



asebio

# Annual Report 2010



## EXECUTIVE SUMMARY

1. Current situation of the Spanish biotechnology sector.....	3
2. New companies created in 2010.....	9
3. Business activity.....	15
4. Industrial property and knowledge generation.....	23
5. Red biotechnology.....	27
6. Green biotechnology.....	31
7. White biotechnology.....	35
8. Financial data.....	39
9. Internationalisation.....	43

## APPENDIX I:

Who's who? Business Partners.....	49
Who's who? Other Organizations Members.....	93

# 1. Current situation of the Spanish biotechnology sector

asebio



## 1. Current situation of the Spanish biotechnology sector

Despite the economic hardships felt in Spain during the 2009 recession, the national biotechnology sector continued to expand, with sector growth rates outperforming those of the previous years.

In 2009, the Spanish biotech sector comprised 1,095 companies that carry out biotechnology activities and 399 companies focused primarily or exclusively on biotechnology (hereinafter biotech companies). A total of 148,648 professionals work in the sector, which generates revenue of € 53,152 million. Biotech companies (those whose principal activity is biotechnology) invoiced € 7,711 million, 15% of the sector total.



Table 1 and Chart 1 present the key findings of the National Statistics Institute (Instituto Nacional de Estadística, INE) 2009 Survey on Technological Innovation in Companies. Despite the economic recession, the sector continued to grow in size, at rates similar to the previous years (see Chart 1): 16.2% in the case of companies using biotechnology and 30.8% in the case of biotech companies. This consolidates the extremely high accumulated annual growth rates recorded since 2005 (23% and 35%, respectively).

This growth can be partially explained by the transversal nature of biotechnology: companies in different sectors are increasingly incorporating more biotech activities in their products and services. This type of growth naturally arises when new emerging technologies become regular features in the productive system.


**Table 1: Main findings on the biotechnology sector, as per the 2009 Survey on Technological Innovation in Companies.**  
Source: INE, 2009 Survey on Technological Innovation in Companies

Main variables	Less than 250 employees	Over 250 employees	2009 total	2008 total	Difference	Growth rate
<b>Companies carrying out biotechnology-related activities</b>	<b>1,017</b>	<b>78</b>	<b>1,095</b>	<b>942</b>	<b>153</b>	<b>16.2%</b>
Companies focusing primarily or exclusively on biotechnology activities	380	19	399	305	94	30.8%
Companies in which biotechnology comprises a secondary business line	142	19	161	225	-64	-28.4%
Companies in which biotechnology is a necessary tool manufacturing tool	495	40	535	412	123	29.9%
Companies that carry out biotechnology R&D activities	681	60	741	662	79	11.9%
<b>Total employment</b>	<b>30,140</b>	<b>118,508</b>	<b>148,648</b>	<b>108,374</b>	<b>40,274</b>	<b>37.2%</b>

*Is continued in the following page.*

**Table 1:** Main findings on the biotechnology sector, as per the 2009 Survey on Technological Innovation in Companies.  
Source: INE, 2009 Survey on Technological Innovation in Companies

Main variables	Less than 250 employees	Over 250 employees	2009 total	2008 total	Difference	Growth rate
Revenue (€ million)	5,528	47,624	53,152	31,101	22,051	70.9%
Biotechnology R&D personnel (number)	5,276	1,565	6,841	6,402	439	6.86%
<b>Total, by job</b>						
Researchers	2,915	986	3,901	3,538	363	10.3%
Technicians and auxiliary personnel	2,361	579	2,940	2,864	76	2.7%
<b>B) Of which: females</b>	<b>2,918</b>	<b>942</b>	<b>3,860</b>	<b>3,654</b>	<b>206</b>	<b>5.6%</b>
Researchers	1,517	555	2,072	1,920	152	7.9%
Technicians and auxiliary personnel	1,401	387	1,788	1,734	54	3.1%
<b>Private internal spending in biotechnology R&amp;D (€ thousand)</b>	<b>350,694</b>	<b>134,772</b>	<b>485,466</b>	<b>460,653</b>	<b>24,813</b>	<b>5.4%</b>
<b>A) By type of expense</b>						
<i>Current expenses</i>	290,587	125,612	416,199	386,260	29,939	7.8%
-Researcher salaries	101,015	41,496	142,511	133,266	9,245	6.9%
-Technician and auxiliary personnel salaries	57,513	17,390	74,903	77,279	-2,376	-3.1%
-Other current expenses	132,060	66,726	198,786	175,716	23,070	13.1%
<i>Capital expenditure</i>	60,107	9,160	69,267	74,393	-5,126	-6.9%
-Land and buildings	13,293	624	13,917	26,498	-12,581	-47.5%
-Equipment and tools	42,553	7,924	50,477	44,944	5,533	12.3%
-Acquisition of R&D software	4,261	612	4,873	2,951	1,922	65.1%
<b>B) By source of funds</b>						
<i>National funds</i>	<b>336,494</b>	<b>97,867</b>	<b>434,361</b>	<b>416,896</b>	<b>17,465</b>	<b>4.2%</b>
-Own resources	217,538	77,087	294,625	296,225	-1,600	-0.5%
-From companies	20,310	6,904	27,213	21,711	5,502	25.3%
-From public administrations	95,325	12,503	107,828	95,650	12,178	12.7%
-From universities	67	715	782	258	524	203.1%
-From private non-profit institutions	3,254	658	3,912	3,053	859	28.1%
<i>International funds</i>	<b>14,200</b>	<b>36,906</b>	<b>51,106</b>	<b>43,757</b>	<b>7,349</b>	<b>16.8%</b>
-From European Union programmes	7,627	411	8,038	6,150	1,888	30.7%
-Other international funds	6,573	36,495	43,068	37,607	5,461	14.5%
<b>% of companies applying for biotechnology patents</b>	<b>14</b>	<b>19</b>	<b>14</b>	<b>11</b>		
<b>Number of patents requested</b>	<b>449</b>	<b>40</b>	<b>489</b>	<b>265</b>	<b>224</b>	<b>84.5%</b>



**Chart 1:** Trends in key indicators.

Source: INE, 2009

Survey on Technological Innovation in Companies


The most salient indicators include the almost 7% rise in the number of biotech R&D personnel employed and the over 5% growth in private R&D expenditure. In addition, companies carrying out biotechnology R&D grew 12%. Other output indicators are also noteworthy, such as the number of patent applications, which virtually doubled (up 85% in the past year). These indicators confirm the efficiency and strength of the national bioindustry sector.

The sector structure remains stable. 93% of the companies using biotechnology had less than 250 employees, a figure which rose to 95% in the case of biotec companies. The INE survey also revealed that biotech companies account for 25% of sector employment, and 15% of the total revenue generated.


In 2009, private internal R&D expenditure in biotechnology exceeded € 485 million, up 5.4% on the previous year. The bulk of these funds were received from Spanish sources (89.5%). Specifically, activities were financed using companies' own funds (67.8%) and, to a lesser degree, funds from public administrations (24.8%). Other companies (6.3%) also account for some funding, as do private non-profit institutions and universities (both with 1%).

With respect to the gender breakdown, the percentage of female R&D professionals in biotech companies remains virtually stable (56%). This percentage rises further in companies with headcounts of over 250 employees, where 60% of employees are female.

As shown in Chart 3, for the first time food sector companies (42%) have taken the lead among companies carrying out biotechnology activities, followed by human health applications (38%). Biotechnology activities are also carried out for environmental applications (18%), animal health and aquaculture (17%), and agriculture and forest production (18%).



**Chart 2:** Trends in number of companies carrying out biotechnology activities. Source: INE, 2009 Survey on Technological Innovation in Companies.




**Chart 3:** Percentage of companies, by area of final application of biotechnology. Source: INE, 2009 Survey on Technological Innovation in Companies.

### Analysis of indicators, by region

The number of companies using biotechnology (Chart 4) has increased in all autonomous communities in Spain, except in the region of Madrid (down slightly in the past year, by six companies). This decline in Madrid furthered Catalonia's lead in biotechnology use (21.19% of national total).

Following Madrid and Catalonia, biotechnology user companies are highest in Andalusia (12.15%), Valencia (9.50%), the Basque Country (8.22%) and Galicia (7.40%). The exceptional dynamism in Cantabria and Castilla-La Mancha, with growth rates of approximately 140% from 2008 to 2009, is especially noteworthy.




**Chart 4.** Geographic breakdown of biotechnology companies. Source: INE, 2009 Survey on Technological Innovation in Companies.

With respect to the number of biotech companies (Chart 5), Catalonia (20.55%) and Madrid (19.30%) are once again at the forefront in terms of critical business mass in a given autonomous community. Growth in both regions hit two-digit figures in the past year (28.13% and 11.59%, respectively). Together, Madrid and Catalonia account for nearly two-thirds of national internal R&D expenditure (34.6% and 29.3%, respectively).

The second tier in terms of number of biotech companies comprises Andalusia (12.28%), Valencia (11.03%), the Basque Country (10.03%), and, somewhat farther behind, Galicia (6.27%). These four autonomous regions recorded significant growth rates, at over 25%.

Lastly, the number of biotech companies doubled in both the Canary Islands and the Balearic Islands, from three to six companies in 2009. In Navarra, in one year alone the number of biotech companies jumped from four to nine.



**Chart 5.** Geographic breakdown of biotech companies. Source: INE, 2009 Survey on Technological Innovation in Companies

## 2. New companies created in 2010

asebio




## 2. New companies created in 2010

The following entities operating in the different Spanish autonomous communities collaborated in this study: BioBasque, IDEA, Castilla y León Regional Government Sector Planning Area, Biocat (BioRegion of Catalonia), Bioaratec (Aragón biocluster), Bioibal (Balearic Island biotech cluster), BioRegion of Andalusia, Biotega, Bioval (Association of Biotech Companies in Valencia), CEEI Asturias, CEEI Valencia, the La Rioja Regional Department of Industry, Innovation and Employment's General Directorate for Innovation, the Sodercan Group, the Murcia Institute for Development, Parque Científico de Madrid, Sodena (Sociedad de Desarrollo de Navarra), Tecnopole (Parque Tecnológico de Galicia) and ZEC (Zona Especial Canaria).

The study identified 57 new companies incorporated in 2010. Once again, the majority of these new biotechnology endeavours were in Andalusia (25%) and Catalonia (23%). Madrid ranks third in this regard (11%), followed by Castilla y León and Valencia (9% each).

Aragón and the Basque Country account for 5% of new companies, while the Balearic Islands, the Canary Islands, La Rioja and Navarra represent 4%.



**Chart 6:** Geographic breakdown of creation of biotechnology companies in 2010. Source: ASEBIO.





## 2. | New companies created in 2010

**Table 2** Biotech companies commencing operations in 2010. Source: ASEBIO

COMPANY	PROVINCE	ACTIVITY
Agrogenera	Zaragoza	Production of fuel crops and maximisation for use in cogeneration or biomass generation plants
Alergenetica	Tenerife	Experimental biotech R&D
AT-Biotech	Málaga	Biotech company working with latest-generation ICT applications and systems, specialised in y online traceabilit systems to identify, monitor, control and follow-up on transplantable organs, blood bags and related devices
Traceability Information System		
Axontherapix	Seville	Development of a new treatment for Parkinson's
BioMass Booster	La Rioja	Technology company developing high-performance germplasm, improving productivity of biomass generation per unit of cultivated surface area, applying genetic engineering tools and techniques
Biomedigen	Valencia	Bovine foetal serum
Bionanoplus	Navarra	Innovate project with strategic approach toward the development of polymeric nanoparticles and microparticles in order to improve the efficacy of biologically active molecules, drugs and other types of molecules
Bioncotech Therapeutics	Valencia	Research, manufacture and sale of anticancer medicines
Biorizon Biotech	Almería	High-value products for intensive and organic farming, cosmetics, pharmacy, animal nutrition, human nutrition, medicine and nutraceuticals
Blue Agro Bioscience	Gipuzcoa	Research, manufacturing and sale of high-performance fertilizers based on bio and nano-technology processes, obtaining efficient and environmentally-sustainable products
Catalunya Genetics & Embryo Transfer	Barcelona	Production, purchase, sale, import and export of substances and products for biotechnological, chemical, food, agricultural, ichthyological and marine uses
CEB CAT LA BALCA	Girona	Project consultant helping to increase knowledge and take the correct decisions regarding the management of the natural heritage
Celgene Research (CITRE)	Seville	Biopharmaceutical company carrying out research into innovative medicines, primarily for treatment of cancer and autoimmune diseases, through biobanks or establishments holding biological samples for diagnostic or biomedical research purposes, organised as a technical unit in accordance with quality, order and use criteria
Desarrollos y Producciones Químicas Movic	Seville	R&D into new plant health formulations in line with the specific needs of target markets (climate, agricultural practices, crops, environmental regulations)
Doc Design	La Rioja	Use of wastes from alcohol and wine production in order obtain active ingredients for cosmetics
Dynamimed	Madrid	R&D and sale of animal health diagnostic products and services
Fenome Biotech	Barcelona	Start-up of the Barcelona Centre for Genomic Regulation
Gennova Scientific	Seville	Manufacturing of products for use in molecular biology and biotech derivatives (recombinant DNA, recombinant proteins, monoclonal antibodies, etc.)
Genometra	Valencia	Bioinformatics consultancy services
Green emission	Zaragoza	Environment
HepaCyL Therapéutics	Valladolid	Development of hepatitis C treatments
Hibricyl	León	Monoclonal antibodies
Img Pharma Biotech	Bizkaia	Drug discovery using not only conventional methods such as radioligand binding and autoradiography but also proprietary high throughput Screening technology based on cell membrane microarrays, isolated from different recombinant cell lines that over express a specific subtype of receptor as well as from organs and tissues of animal models such as rats, mice, etc.
Imicroq	Tarragona	R&D, manufacturing and sale of integrated microsystems
ImmunNovative Developments	Barcelona	R&D&I, consultancy, and manufacturing, sale and distribution of products and/or services in connection with the biomedical sector, especially sepsis prevention and
Infiquis	Madrid	Functional characterisation of chitin, chitosan and their derivatives at the request of companies, research groups, and individuals
InfoGenia SCP	Barcelona	Biomedicine consulting
Ingesmasa	Zaragoza	Food genetics
Innovagenomics	Salamanca	Genetic diagnostic tests
Instituto de Informes Medicinales	Tenerife	Experimental research and development in natural sciences and techniques
Legsgo Bioprotésica	Seville	R&D&I, design, manufacture and sale of prosthetic components for lower appendages
Lykera Biotech	Barcelona	R&D projects in life science therapy and diagnosis. Sale and management of results
Metis Biomaterials	Valencia	Tissues and materials engineering
MSS Innovación	Balearic Islands	Research and innovation in gastronomy and application of V gamma products and research
Nanoinnova	Madrid	Manufacturing of applicable products comprising carbon-based nanomaterials and growth instruments, as well as R&D&I studies (projects unit)


*Is continued in the following page.*

**Table 2** Biotech companies commencing operations in 2010. Source: ASEBIO

COMPANY	PROVINCE	ACTIVITY
Nanomol Technologies	Barcelona	Technological solutions in the area of molecular materials
Natac Biotech	Madrid	R&D and sale of healthy ingredients for use in functional foods and food supplements, as well as of natural pharmaceutical active ingredients
Oncomatrix	Bizkaia	Development of biological drugs for new target therapies, located in the extracellular matrix, to fight invasive cancer, as well as products to diagnose and provide prognosis for the aggressivity of tumours and the individual response to pharmacological treatment
Pharmactive Biotech Products	Madrid	Development and manufacturing of new active ingredients for the pharmaceutical and food industries
Pharmamodelling	Navarra	Consultancy in comprehensive analysis services for data from pharmacological preclinical and clinical trials, rendered to the pharmaceutical industry, clinics, hospitals and research departments of pharmaceutical laboratories
Plasmia Biotech	Barcelona	Production, import, export, distribution and sale of medical, cosmetic and consumer products
Proton Laser Applications	Salamanca	Biomedicine research and development
Quospharma	Madrid	Chemical synthesis of structurally-complex natural products. Main areas of service: oncology, lipid regulators, analgesics, advisory and comprehensive scientific consultancy
RadisMed	Barcelona	Development of medical solutions
Rekom Biotech	Granada	Development of recombinant proteins, primarily focused on the design and production of antigens applied to diagnose infectious diseases in humans and animals
Resbiagro	Seville	Development of own knowledge and technology in order to use microorganisms as effective allies to provide biotechnological solutions to the agrofood, energy and environmental sectors through top-quality and environmentally-friendly products and services
Sagetis Biotech	Barcelona	Design, synthesis, production and sale of biomaterials and related materials
Selten Diagnosis	Seville	Research and diagnosis of rare diseases
STAT-Diagnostica & Innovation	Barcelona	Development of scientific-medical equipment and technology
Stem Center	Balearic Islands	Research in new applications to cure diseases using stem cells taken from adipose tissue
Stevigran	Granada	Manufacturing of natural zero-calorie sweeteners from the Stevie rebaudiana plant, as well as plant preparations using industrial technology, for sale in supermarkets and herbalist shops
Technical Proteins Nanobiotechnology	Valladolid	Design, development and distribution of biomaterials obtained from recombinant protein polymers with high potential for advanced biomedical applications
Tharsis BioMed	Jaén	Development of products and the provision of services related with personalised medicine, and the improvement of treatments through the development of innovative molecular diagnostic products
Tictough, Tecnología y Bienestar	Seville	Advanced remote monitoring of vital signs, serving as a reliable and direct link between patients and their public or private health centre
VBF	Valencia	Elimination of biological waste
Vetgenomics	Barcelona	Universitat Autònoma de Barcelona (UAB) Veterinary School Centre, expert in animal genomics, offering genetic analysis services for domestic species and wild fauna, as well as projects with companies
Vitalis Salud Granada	Granada	R&D in devices for health promotion and disease prevention, based on medical studies

### 3. Business activity

asebio



### 3. Business activity

---

#### Alliances and business development

---


In measuring business development, the study took into account any formal agreements between at least one Spanish biotech company and another entity that entail an explicit undertaking to secure certain shared goals (R&D, production, sales, etc.), reflected in the strategy of the participating organisations.


Different agreement formats (co-marketing, co-development, product and market exchange, etc.), other than conventional sale-and-purchase or service provision relationships, were looked at in the study. This year, for the first time, the study takes into account collaborative efforts carried out under national (such as CENIT) and international (FP7, ERA NET, etc.) programmes.

In order to gain a clear overview of alliances in Spain, in the case of multinational companies, ASEBIO's study only considers those agreements in which one partner is a Spanish entity or is focused specifically on the Spanish market (through distribution, sales, etc.).


In 2010, a total of 143 alliances were identified, of which 45% were carried out in the public arena, 33% with another biotech company and 22% with user companies.

The majority (65%) of alliances or collaborations were established with Spanish entities, followed by entities from Europe (18%), the US (6%) and Asia and Latin America (5% each).





**Chart 7:** Breakdown of alliances in the Spanish biotechnology sector in 2010, based on partner profile Source: ASEBIO




**Chart 8:** Breakdown of alliances in the Spanish biotechnology sector in 2010, based on origin of partner Source: ASEBIO

## Product launches

ASEBIO carried out a study among its member entities on the products and services launched in the market in 2010.

A total of 71 products/services were identified, the majority of which relate to the healthcare arena (62%), followed by agrofood products (11%), industrial processes (12%), products/services for human and animal health (10%) and animal health (5%).

Table 3 provides a complete list of the products and services introduced, the area of application and type of product (diagnostic, therapeutic, industrial, software, bioinformatics service, development service, research service, functional food, etc.).



**Chart 9:** Breakdown, by sector of application, of products and services launched by Spanish ASEBIO member biotechnology companies in 2010 Source: ASEBIO

**Table 3** Products and services launched in 2010 by Spanish ASEBIO member entities.  
Source: ASEBIO

Company	Product/service	Type	Area
AB Biotics	AB-LIFE (probiotic cholesterol reducer)	Product (functional food)	Agrofood
Advancell / Solvo Biotechnology	PreadyPort MDR1 (line of cellular reagents for measuring cellular transport of drugs and other compounds)	Industrial product	Human health
Araclon Biotech	Abtest kit (appropriate selection of patients in early stage, as well as follow up of the response of medicines under development)	Diagnostic product	Human health
Arquebio	PBEA (biocatalysis platform for oxidation of methyl groups)	Industrial product	Industrial processes
Arquebio	PESA (biocatalysis platform for esterification)	Industrial product	Industrial processes
Arquebio	PECA (aldol condensation biocatalysis platform)	Industrial product	Industrial processes
Biobide	Steatosis trials in zebrafish (test to evaluate the ability of different substances to induce/protect against steatosis)	Research service	Human health
Biokit	Biorapid MONONUCLEOSIS 25 Test (qualitative tests to detect heterophile antibodies for mononucleosis infections)	Diagnostic product	Human health
Biomedal Diagnostics	GlutenTox Home (test to identify the presence of gluten in food)	Diagnostic product	Human health
Biomedal Diagnostics	GlutenTox Sticks Especial Chocolate (strips to detect gluten in food that contains chocolate)	Diagnostic product	Agrofood
BIOPOLIS	Metabolomics services (licensing of the probiotic Bifidobacterium with anti Helicobacter pylori activity)	Diagnostic product and research service	All areas
BTI Biotechnology Institute	PTD Plasma Transfer Device (sterile, disposable plasma fractionation kit)	Therapeutic product	Human health
Canvax	pSpark cloning vector	Industrial product	Industrial processes
CIBER-BBN / Bioforge Group / Universidad de Valladolid	Injectable materials for regenerating damaged tissue	Therapeutic product	Human health
CIBER-ER / CSIC	Albinochip (development of a universal albinism genetic diagnostic system)	Diagnostic product	Human health
Era7	NGS and Bacterial Genomics (semiautomatic notation system for bacterial genome, based on cloud computing)	Bioinformatics product/service	Human and animal health
Gendiag	Sudd inCode (clinical-genetic assessment service to aid in diagnoses of sudden cardiac death)	Diagnostic product	Human health
Genzyme	Mozobil® (medicine for patients with lymphoma and multiple myeloma that do not mobilise sufficient stem cells for autologous bone marrow transplants)	Therapeutic product	Human health
Histocell	Histocell CTTS Technology (innovative technology for transport of cells and tissues)	Diagnostic product	Human health
Iden Biotechnology	P200930009 (procedure for producing transgenic plants with high content and performance in starch and biomass)	Industrial product	Agrofood
Igen Biotech	New DNA extraction kit (for use in critical sampling, such as amniotic fluid or forensic tests, where time is a decisive factor and initial material is scarce, and where high-quality DNA is needed for subsequent genetic tests)	Diagnostic product	Human health
Igen Biotech	Igen Biotech genome DNA extraction kit (first high-quality DNA extraction kit, specially designed for amniotic fluid samples - prenatal diagnosis)	Diagnostic product	Human health
Igen Biotech	R&D services (biomedical)	Research service	Human health
Igen Biotech	R&D services (analysis of protein and antibody activity)	Research service	Human health
Igen Biotech / IRYCIS	Aptus Biotech (service specialised in selecting aptamers for specific targets)	Research service	Human and animal health
Ingenasa	INGEZIM β-LACTOGLOBULINA (double antibody enzyme immunoassay for detecting and quantifying β-Lactoglobulina residue in food products)	Diagnostic product	Human health

*Is continued in the following page.*

**Table 3** Products and services launched in 2010 by Spanish ASEBIO member entities.  
Source: ASEBIO

Company	Product/service	Type	Area
Ingenasa	INGEZIM PRRS DR (new diagnostic test concept applied to controlling porcine reproductive and respiratory syndrome)	Diagnostic product	Animal health
Ingenasa	INGEZIM PPA CROM (detection of specific African swine fever virus antibodies, in porcine serum samples)	Diagnostic product	Animal health
Ingenasa and CISA-INIA	Ingezim West Nile Compac (new diagnostic test for detecting specific West Nile virus antibodies)	Diagnostic product	Human and animal health
Ingredientis Biotech	Product development, use of by-products, characterisation of foods, and a wide range of services to support innovation in all types of food products. Optimisation of by-products	Development service	Agrofood
Ingredientis Biotech	Identification of bioactive compounds, evaluation of biological activity, bioactive-delivery compounds (discovery platform for bioactive compounds that regulate key molecular targets in controlling body weight and preventing obesity and related diseases)	Research service	Human health
Ingredientis Biotech, Oncología Básica and the Universidad de Granada Clinic	Biological tests for assessing hormonal activity of compounds used in food	Diagnostic product	Human health
Instituto de Medicina Genómica	GMO extraction kit (kit to isolate and purify DNA from a wide variety of food samples, including both raw materials and processed food and fodder)	Diagnostic product	Agrofood
Instituto de Medicina Genómica	TaqMan GMO Screening Kit (kit for analysing transgenic events in food products)	Diagnostic product	Agrofood
Instituto de Medicina Genómica	TaqMan Roundup Ready Soya Quantification Kit (kit for quantifying transgenic soybeans in food products)	Diagnostic product	Agrofood
Instituto de Medicina Genómica	CGH Arrays (compared genome hybridation service for analysing genetic material gains and losses)	Diagnostic product	Human health
Instituto de Medicina Genómica	Sequence capture (capture and enrichment of genes for ultrasequencing)	Development service	Human health
Integromics	SeqSolve (specific next generation sequencing software)	Bioinformatics product/service	Human health
Intelligent Pharma	CHIRON (technology enabling quicker optimisation of molecules, determining the most active compounds and drastically reducing experimental and synthesis efforts)	Bioinformatics product/service	Human and animal health
IUCT	New process for obtaining S-50 (new optimised process for obtaining S-50, a second-generation biofuel based on renewable raw materials)	Industrial product	Industrial processes
IUCT	Biomaterials (polymers for implants to treat osteoarthritis)	Therapeutic product	Human health
IUCT	Biosolvents for metal degreasing applications (collection of solvents from renewable raw materials for metal degreasing)	Industrial product	Industrial processes
IUCT	Biosolvents for biofuel synthesis processes (collection of solvents from renewable raw materials for use in biofuel synthesis processes)	Industrial product	Industrial processes
IUCT	Biosolvents for agro-chemical formulations (collection of solvents from renewable raw materials for use in agro-chemical formulations)	Industrial product	Industrial processes
IUCT	API biosynthesis (use of industrial biotechnology for API biosynthesis, developing the platform for anticarcinogen and antiviral synthesis)	Development service	Human health
Neuron BPh	Safety and efficacy studies in zebrafish models (tool for evaluating the biosafety and efficacy of ingredients using a vertebrate animal model (zebrafish))	Research service	Agrofood

*Is continued in the following page.*

**Table 3** Products and services launched in 2010 by Spanish ASEBIO member entities.  
Source: ASEBIO

Company	Product/service	Type	Area
NorayBio	NorayLIMS OMICS (bioinformatics tool for managing data derived from OMICAS research)	Bioinformatics product/service	Human and animal health
OPERON	Simple 2A-Bdiff (quick test to detect Clostridium difficile A and B toxins in faeces)	Diagnostic product	Human health
OPERON	Simple HYPERdiff (quick test to detect Clostridium difficile hypervirulent B toxin in faeces. Ribotipado: 017 and 027)	Diagnostic product	Human health
OPERON	OpeGen YcromeStrip (molecular diagnosis - deletion of chromosome Y)	Diagnostic product	Human health
OPERON	OpeGen CeliacStrip (molecular diagnosis - coeliac disease)	Diagnostic product	Human health
OWL Genomics and CIC bioGUNE	Tool for early diagnosis of non-alcoholic fatty liver disease	Diagnostic product	Human health
PharmaMar	Yondelis for ovarian cancer	Therapeutic product	Human health
PharmaMar	Yondelis for soft tissue sarcoma	Therapeutic product	Human health
Progenika	IDHPA (blood type identification tool)	Diagnostic product	Human health
Progenika	Idcore (blood type identification tools)	Diagnostic product	Human health
Progenika	Promonitor kit (enables closer monitoring of patients with chronic inflammatory illnesses, such as arthritis or Crohn's disease)	Diagnostic product	Human health
Proteomika / Hospital Donostia	PNEUMOarray (chip to optimise monitoring and detection of pneumonia and other pneumonic illnesses)	Diagnostic product	Human health
Secugen	DMAE test (genetic risk test for age-related macular degeneration - ARMD)	Diagnostic product	Human health
Sistemas Genómicos	NGS - Cardio (diagnostic service analysing 72 genes connected with sudden death, using massive sequencing)	Diagnostic product	Human health
Sistemas Genómicos	NGS - ONCO (diagnostic service analysing genes connected with sudden death, using massive sequencing)	Diagnostic product	Human health
Sistemas Genómicos	NGS - Exoma (exome research service)	Research service	Human health
Sistemas Genómicos	CGH Array for 24 chromosome PGD	Diagnostic product	Human health
Sistemas Genómicos	Fluorescence in situ hybridization (FISH) in sperm (detection of 5, 7 and 9 chromosome aneuploidy)	Diagnostic product	Human health
Sistemas Genómicos	Fragmentation of sperm DNA (determination of apoptosis using the TUNEL technique)	Diagnostic product	Animal health
Sistemas Genómicos	Characterisation of RNA alternative splicing events using FRET (development of a new method based on the Förster Resonance Energy Transfer (FRET) microscopic technique to characterise RNA alternative splicing events)	Research service	Human and animal health
Stem Center	Surgical treatments with stem cells from adipose tissue	Therapeutic product	Human health
Valentia Biopharma	Baculovirus expression system	Diagnostic product	Human health
VivaCell Biotechnology	Biological activity certification service (at preclinical level, for companies producing growth factors and recombinant proteins in general)	Diagnostic product	Human health
X Pol Biotech S.L.	Human DNA polymerase mu (only for use in research in in-vitro mutagenesis procedures, among others)	Research service	Human health
X Pol Biotech S.L.	Human DNA polymerase mu-H6 (only for use in research in in-vitro mutagenesis procedures, among others)	Research service	Human health

$\alpha$ 
 $\xi$ 
 $\varpi$ 
 $\beta$ 
 $\rho$ 
 $\sigma$ 
 $\omega$ 
 $\lambda$ 
 $\tau$ 
 $\nu$ 
 $\pi$ 
 $\theta$ 
 $\kappa$

## Strategic priorities

Each year, ASEBIO conducts a survey among its members to ascertain their strategic priorities for the future and to analyse progress over the past years.

As shown in the following table, both internationalisation and the acquisition of knowledge and/or technologies continue to be the top priorities for Spanish entities.

One of the chief goals for biotech organisations is to begin clinical trials/field experiments/scale-up phases in 2011. This is one of the priorities that has acquired the most importance over the past year.

Creating alliances with other user companies and with other biotech companies have lost relative importance (down two points) compared to the previous year.



**Table 4** Analysis of strategic priorities of Spanish biotechnology companies for 2011, based on a survey of ASEBIO members (in bold: main variations and priorities) Source: ASEBIO

Priorities	Relevance	Variation compared to 2010 position	
Internationalisation	2.95	/=/	0
Acquire knowledge and/or technology	2.87	/=/	0
Begin clinical trials/field experiments/scale-up phases	2.78	▲	5
Product launches	2.77	/=/	0
Create alliances with other user companies (pharma, food industry, etc.)	2.74	▼	-2
Contract or create alliances with public centres	2.46	▲	1
Technology licence-out	2.46	/=/	0
Create alliances with other biotech companies	2.34	▼	-2
Expand operations to other business areas	2.05	▲	1
Recruit foreign professionals	1.67	▲	2
Technology license-in	1.54	/=/	0
Create a joint venture	1.52	▲	1
Refocus R&D activities	1.44	▲	1
Refocus product development	1.31	▲	1
Outsource production	1.17	▲	1
Merge with another company	0.48	▲	2
Acquire another company	0.47	▲	2
Downscale operations	0.38	▼	-1

## 4. Industrial property and knowledge generation

asebio



## 4. Industrial property and knowledge generation

### Industrial property

This study was prepared in accordance with the methodology redesigned by Clarke Modet and the Parque Científico de Madrid Foundation.

In the first stage, patents were located using the international patent classification (IPC) system. The data obtained was sifted using the Thomson and Mercanet databases. In addition, the public databases of various patent offices were consulted, including the Spanish Patents and Trademark Office (SPTO), the European Patent Office (EPO), the United States Patent and Trademark Office (USPTO), the Japan Patent Office (JPO) and the World Intellectual Property Organization (WIPO).

The search revealed 694 inventions (applications in process or granted) published in 2010 under the name of Spanish biotechnology sector entities. This represents an increase of almost 60% compared to the previous year.

Table 5 provides an absolute-value breakdown of the 694 inventions, as per the scope of protection sought (Spain, Europe, US, Japan or PCT) and the type of document (application or grant).

**Table 5** Number of applications and grants - Spanish biotechnology entities (2010)

Patents*	SPTO	EPO	USPTO	JPO	PCT	TOTAL
Applications	228	53	57	4	78	420
Grants	221	30	21	2	-	274
TOTAL	449	83	78	6	78	694

\* SPTO: applications and grants for Spanish patents. EPO: European applications. USPTO: applications and grants for US patents. JPO: applications and grants for Japanese patents. PCT: applications under the Patent Cooperation Treaty.

According to the breakdown of applications and grants, approximately 61% of inventions relate to patent applications. The highest percentage of these applications were brought before the SPTO (54%), with those filed with WIPO (19%), the USPTO (14%) and the EPO (13%) considerably behind. Japanese applications were nominal, representing only 1% of all applications. With respect to patents granted (39%), the Spanish industrial property protection system once again occupies the top position, with 81%. Grants of Japanese industrial property protection represent only 1%.

In 2010, the CSIC filed the largest number of patent applications and grants among Spanish biotechnology-related companies, with 156 inventions (Chart 4.1). The CIMA Biomedicine Project came in second, with 20 applications, followed by Laboratorios Esteve (13), PharmaMar (9), Grifols (9, of which 5 were filed by Grifols Engineering and 4 by Grifols, S.A.), the Institut Univ. De Ciència i Tecnologia (IUCT) (8), Fina Biotech (7), and Biomedal, Oryzon Genomics and Probelte Biotechnology (6 each) and Neuron Biopharma (5).






Chart 9. Provides a breakdown of patent applications and grants of these entities.

## Scientific production

Each year, ASEBIO analyses articles published in top-tier scientific journals by Spanish biotechnology companies and by multinational research laboratories with offices in Spain.

This particular study does not take into account communications or displays at conferences or trade fairs, or chapters published in books. ASEBIO also excludes publications signed by research centres or by universities which do not disclose their relationship with corporate study undertakings.

The study revealed that in 2010, a total of 133 publications were issued by 25 Spanish companies. The most active companies in that regard were Pharmamar (23 publications), BTI ImasD (15), Neocodex (13), Araclon Biotech (11), Digna Biotech (10), Biomol Informatics and Sistemas Genómicos (8 each) and Esteve and Neuron BPh (7 each).

## 5. Red biotechnology

asebio



## 5. Red biotechnology

### Development of human health therapies

In the field of neuroscience, Neuron BPh patented a new compound for the potential treatment of Alzheimer's. Noscira, a Zeltia Group company, unveiled the results of a Phase II clinical trial with its compound Nypta ® (Tideglusib), also for the treatment of Alzheimer's.

In the field of oncology, GP Pharm (Lipotec Group) closed the recruitment portion of the GP/C/02/SAR clinical trial for the research product Sarcodoxome® (Doxorubicin (liposomal)), expecting that preliminary results will demonstrate the safety and efficacy of the product as well as the pharmacokinetic profile. PharmaMar (Zeltia Group) announced the launch of a clinical trial to register Aplidin® (plitidepsin) together with dexamethasone, compared to dexamethasone as a single agent, for the treatment of multiple myeloma.

An experimental drug created by AB Therapeutics, a subsidiary of AB Biotics, halted lung tumour growth by 70%, thanks to a study on membrane-lipid therapy, which alters the membrane of malignant cells and attacks the tumour without resistance.

Histocell and Ferrer signed an agreement to develop a new cellular therapy medicine to regenerate joint cartilage using non-invasive surgical techniques.


Araclon Biotech recently began clinical trials of its Alzheimer's vaccine. Although the trials will be carried out with the assistance of European health centres, once all protocols have been completed, the vaccine would be sold first in the US and in parts of Asia and South America.



### Human health diagnosis products and services

Oryzon Genomics received approval to perform clinical diagnoses on humans at its facilities. Among its pipeline products, the two most advanced are a biomarker to diagnosis endometrial cancer and a treatment for Huntington's disease. In addition, through their joint venture GEADIC and in collaboration with Hospital del Valle Hebrón, Oryzon Genomics and the Catalan pharmaceutical Reig-Jofré continued to make headway in developing their DNACHip for detecting endometrial cancer using uterine aspiration.

The Instituto de Medicina Genómica (IMEGEN) designed the necessary laboratory protocols for the molecular genetic diagnosis of over 400 hereditary diseases.



A Basque consortium, formed by CIC microGUNE, Instituto BioDonostia, Proteomika and Abyntek (Progenika Group), is working to develop a microsensor to monitor the evolution of autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis and psoriasis.

Sistemas Genómicos has launched two new guided ultrasequencing services, covering needs in two key areas, namely oncology and cardiology.

AB-Biotics has developed Neurofarmagen, a genetic test involving a simple saliva analysis that makes it possible to study and evaluate the likelihood a patient will respond to therapy in the treatment of psychiatric illnesses such as depression, schizophrenia and bipolar disorder. Araclon Biotech is researching a kit for the early diagnosis of Alzheimer's, identifying incipient development of the disease in patients.

## Bioinformatics

NorayBio unveiled a new software for managing and analysing clinical and experimental data. This software, NorayLIMS OMICS, makes it possible to intuitively interpret data obtained, thanks to its data input, analysis, management and consultation tools.

Biomol-Informatics presented its new BIOMOL-NGS system (solutions for analysing next generation sequencing data) in cooperation with Parque Científico de Madrid, and is developing tools for the rapid and effective analysis of data from large-scale next generation sequencing projects, including complete genome resequencing.

Era7 Bioinformatics combines next generation sequencing (NGS) data analysis with the power of cloud computing, thanks to its capacity to use IaaS (Infrastructure as a Service) via Amazon's cloud computing services.

## 6. Green biotechnology

asebio



## 6. Green biotechnology

---

### Agriculture

---

According to the latest ISAAA (International Service for the Acquisition of Agri-biotech Applications) data, Spain ranks number sixteen in production of genetically-modified corn. In addition, for the first time ever, over 1,000 million ha. of biotech crops are in production, with 29 producer countries.

In Spain, thirteen years after the first transgenic corn seeds were planted, the crops have yielded uncountable benefits. Genetically-improved corn accounts for 24% of the land used for corn growing in Spain. This type of corn naturally wards off the corn borer pest, boosting productivity/ha. and reducing water consumption/kilo produced. The use of plant health chemicals has also been reduced, protecting natural fauna and biodiversity. In addition, given that genetically-improved corn does not require treatments against corn borers, atmospheric CO<sub>2</sub> emissions have been reduced.

With respect to other agricultural areas, the Basque technological corporation Tecalia is participating in and coordinating the European BIMOSYN project. This project aims to develop lower-biocide, environmentally-friendly pesticides that are not harmful to humans.

In addition, through a FP7 project, NEIKER-Tecalia is addressing genotyping and the possibilities of introducing in Europe the two species identified for substituting imported natural latex: the Guayule (*Parthenium argentatum*) bush and the Russian dandelion (*Taraxacum kok-saghyz*). The genetic study of both plants will primarily serve to generate commercially-viable specimens capable of producing greater amounts of latex.

### Functional foods

---

AB-Biotics unveiled AB-LIFE, a nutritional ingredient for reducing cholesterol levels by 14%. The probiotic formula comprises three strains of *Lactobacillus plantarum*, selected from among over 500 wild strains.

Neuron BPh and Innofood are participating in the Neuro-Extract project to design a process for fully optimising by-products generated in the production of tropical fruits such as mangos, avocados and cherimoyas. The most advanced results obtained to date have demonstra-



ted the neuroprotective and antioxidant activity of compounds taken from mango leaves, which is of special interest as a potential post-ictus therapy.

The CENIT HENUFOOD project is conducting research in order to improve the health of the Spanish population through food. Under the leadership of Gallina Blanca Star, 11 hospitals, Spanish research centres, and eight other companies participate in the project. Collaborators include 2B Blackbio, which is working to develop tools to identify biomarkers, and Probelte Bio, which is researching biomarkers in connection with metabolic syndrome and cardiovascular protection.

Ingeniatrix and Pevesa launched the NanoInd research project, aimed at designing and producing nanocapsules that, using food products as vectors, are able to release active ingredients to the body on command.

Agrasys, which carries out R&D in new high added-value plant varieties, launched Tritordeum, a new type of cereal, in the European market. This cereal is the result of hybridisation between durum wheat and a wild barley found in Chile and Argentina (*Hordeum chilense*), and provides health benefits as well as organoleptic qualities and a composition that make it ideal for developing new innovative food products.



### Food quality and control technologies

Biomedal's diagnostics, division, Biomedal Diagnostics, has been working to develop reliable techniques to detect gluten in food products. In the past year, the company launched GlutenTox Home, an innovative personal kit for detecting gluten.

Laimat is developing highly-sensitive and selective electrochemical sensors to detect and quantify analytes.

The Instituto de Medicina Genómica (IMEGEN) developed two diagnostic kits to quantify transgenic soybeans in food products and to analyse transgenic events in food.

Neuron BPh created a tool to assess biosafety and efficacy of ingredients using a vertebrate animal model (zebrafish).

Ingredientis Biotech, in collaboration with researchers from the Oncología Básica Group and the Universidad de Granada Clinic, designed a battery of biological tests to assess hormonal activity of compounds used in food.

The Cadiz-based company Bionaturis has implemented methods to detect and eradicate fungus contaminating culture mediums, as part of a study receiving the excellence rating by the Andalusia Regional Department of Innovation, Science and Companies.

## 7. White biotechnology

asebio



## 7. White biotechnology

### Biotechnological applications for energy production

Neiker-Tecnalia launched a new technological research and development line addressing photosynthetic generation of biomass with a high energy content, aimed at obtaining biofuels.

The Instituto Biomar completed the selection process of 2,500 strains of microorganisms collected from different seas (the Caribbean Sea, Norwegian Sea, etc.) and has begun its search for a partner in order to verify, at industrial level, the ability of these microorganisms to produce biodiesel.

The Valencia-based company Biopolis is working to identify and improve microbe strains and to develop processes to obtain bioalcohol from industrial by-products.


Neuron BPh secured a patent for an improved biodiesel production procedure. This patent protects MicroBiOil® technology in connection with second-generation biodiesel production.

IUCT developed a new process for obtaining biofuel for diesel motors, drawing from residual glycerine from the biodiesel industry (IUCT-S50). This process contributes major improvements to the industrialisation phase.

Synergia Bio, the Instituto de Biología Molecular y Celular de Plantas CSIC, Repsol and four European partners rolled out a project to produce biofuel from *Euphorbia lathyris* hydrocarbons. This plant requires little water and nutrients and is used for its hydrocarbon extracts, not oil.

### Bioprocesses

Applus+ joined 28 other companies led by Fagor Electrodomésticos in order to research new active ingredients for detergents. In this project, Applus+ and Henkel will collaborate with Leitat in the areas of energy efficiency of washing machines, the design of minimal detergent bases and the evaluation of primary detergent efficacy.





In collaboration with Cotton Processing Textile Industrial Association (Asociación Industrial Textil de Proceso Algodonero, AITPA), LEITAT has developed an enzyme pre-treatment process for cotton that reduces energy and materials costs in this fabric preparation stage.

In 2010, IUCT licensed a patent for the use of solvents in degreasing metals to a German multinational.

### Biopolymers and bioplastics

In the past year, Neiker-Tecnalia identified a natural biopolymer called chitosan as an alternative to growth antibiotics for ruminants.

LEITAT currently participates in SAFEPROTEX, a European project focused on R&D in new personal protection equipment. One of the aspects researched by the centre is the use of chitosan microspheres as an antimicrobial element in textiles. In addition, the company participates with other entities in the European ALGAEPACK project, which aims to develop new polymers for applications, both in packaging and in films for agricultural uses, based on polyhydroxyalkanoates (PHA) obtained from microalgae cultures.

IUCT has identified a family of exopolysaccharide (EPS) biopolymers that can be used to treat osteoarthritis injuries by mimicking the nature of the joint matrix. In addition, these compounds can improve aspects such as mechanical resistance and biocompatibility and can contribute to regulating differentiation of chondrocytes and homeostasis of the extracellular matrix.

The MIPFOOD project, under the leadership of Mahou-San Miguel and with technical coordination by GAIKER-IK4, aims to develop "active packaging" and "smart labels" that increase and ensure the useful life and quality of packaged products. In order to achieve this ambitious target, molecular imprinted polymers (MIP) will be developed to "trap" agents causing deterioration in foods and beverages.

## 8. Financial data

asebio



## 8. Financial data

---

The largest business endeavour in 2010 was carried out by GP-Pharm (Lipotec Group), for a total of € 20 million.

Noscira carried out the second-largest biotech sector transaction during the year, in excess of € 19 million.

TCD Pharma's first-ever operation, aimed at developing cancer diagnostic and therapy products, was also noteworthy, at € 6.5 million.

Other large-scale operations include those undertaken by Digna Biotec, which in late 2010 approved a capital increase of € 4.5 million, recently subscribed and fully paid by its long-standing shareholders; by Cellerox, with over € 4 million contributed by several investors; and by Proretina Therapeutics, with € 2.5 million contributed by the founding partners, Caja Navarra, Clave Mayor, Inverready, Sodena and other public entities.

Omnia Molecular obtained € 2.1 million following its second round of financing, in which La Caixa, the company's executive team and ENISA participated.

Both Neuron BPh, which researches neurodegenerative diseases, and Palo Biopharma, which focuses on research and development of new molecules to treat cardiac illnesses, obtained € 2 million in their respective capital increases.

As reported by the Spanish Venture Capital Association (Asociación Española de Capital Riesgo, ASCRI) in its latest 2010 Venture Capital study, the biotechnology sector ranks third in terms of number of venture capital transactions, behind only the IT and industrial products and services sectors. However, the sector ranks twelfth in terms of volume of venture capital investments. This situation has been observed in the past several years: although the biotech sector is one of the sectors with the greatest number of transactions, the amount of these investments is not especially high.




The Mercado Alternativo Bursátil (MAB, Alternative Stock Market) is a highly recommendable forum for biotech SMEs that wish to access new sources of financing for their research projects and development and growth plans. And so, in 2010, two Biotec companies entered the MAB, Neuron BpH and AB-Biotics.

According to the European Trade Association for Business Angels, Seed Funds, and other Early Stage Market Players (EBAN), in 2009 the biotechnology sector ranked third in Europe (behind ITC and creative industries) in terms of the amount invested by business angels.



## 9. Internationalisation

asebio



## 9. Internationalisation

In 2010, for the third year in a row, ASEBIO conducted a survey on internationalisation among its members. The main findings of this survey are set out below.

Approximately 88% of ASEBIO members carried out some type of international activity in 2010 (compared to 32% in 2009). This considerable increase is due to several factors: firstly, the survey is more representative, as it was completed by over 60% of members, and secondly, there has been a decided push for internationalisation within the sector.

**Table 9 Main international activities carried out by ASEBIO member companies in 2010 \*ASEBIO**

Research collaboration/alliance	70.0%
Export of products/services	56.7%
Seventh Framework Programme	53.3%
Licensing-out	30.0%
Licensing-in	23.3%
Production plants located abroad	20.0%
Sales office	16.7%
Representation office	13.3%

\*The % indicates the number of ASEBIO member companies carrying out each activity



As in 2009, the average contribution of international activities to revenues of these companies was approximately 26% of the total.

Other survey data reveal the importance that the international arena is acquiring among ASEBIO member companies. Perhaps the most noteworthy finding is that 51% of companies have an international department, compared to 31% in 2009.

The main markets for exports are the USA and the EU (primarily the UK, France and Germany) and, to a lesser degree, Switzerland and Canada.

The top-priority markets in the internationalisation strategies of companies are as follows (as a percentage of the total responses received):

1. EU	89%
2. USA	83%
3. Japan	37%
4. Brazil	32%
5. Canada	29%
6. China	26%
7. Switzerland	20%
8. Israel	17%
9. Middle East	14%
10. Argentina	14%
11. India	14%
12. Australia	12%
13. Chile	9%





According to the survey, 79% of respondents consider that the main obstacle to internationalisation is the lack of funds. Although to a lesser degree, respondents also cited the lack of specific information on internationalisation. The companies surveyed therefore call for activities that focus on prospection in markets and international negotiation.

ASEBIO member companies consider that the most useful internationalisation activities relate to participation in partnerships. More than 82% of companies surveyed consider this activity to be very useful or essential, followed by participation in trade fairs and in Biospain 2010 (over 60%).

Of those companies surveyed that have no prior experience in internationalisation, 57% deem it to be a short-term top-priority objective. 84% consider that internationalisation is important or vital. The main reason cited by companies for not having launched internationalisation processes is that they prefer to first consolidate their positions in Spain, prior to beginning any international activity.

In terms of the preferred type of activity to be carried out in the future with foreign companies and/or institutions, the companies surveyed cited research alliances and collaboration, followed by product licensing, the export of products and/or services, technology transfer and the search for investors.

Over 70% of companies are familiar with the activities and assistance provided by ASEBIO and other institutions in order to promote internationalisation.

### Investment abroad

ASEBIO members not only look to increase their international revenues through the export of products and services, but they also invest abroad, establishing subsidiaries, branches and representation offices.

ASEBIO member companies currently have direct presence in 30 countries in North America, South America, Europe, Asia, Africa and Oceania.




Chart 10: International presence of ASEBIO member companies

Country	No. of subsidiaries	Country	No. of subsidiaries
USA	13	France	2
Mexico	7	India	1
Portugal	6	Czech Republic	1
Brazil	5	Australia	1
Germany	5	Singapore	1
Italy	5	Slovakia	1
Poland	4	Malaysia	1
China	3	Thailand	1
Chile	3	United Arab Emirates	1
Japan	3	Colombia	1
Argentina	3	Uruguay	1
UK	3	Venezuela	1
Sweden	2	Morocco	1
Turkey	2	Angola	1
Dominican Republic	1	Jordan	1

The majority of offices opened abroad by ASEBIO member companies are in the EU (36%) and Latin America (27%). The USA ranks number three (16%), followed by Asia (more than 12%), which saw the largest growth during the year, from five subsidiaries or representation offices to ten in 2010.

A list of member biotech companies and the countries in which they have a representation office/subsidiary/sales office is as follows:

**Alphasip:** USA

**Biokit:** USA

**Biotoools:** Brazil, India (through a joint venture)

**BTI Institute:** USA, Mexico, Portugal, Italy, Germany

**Esteve:** Germany, China, USA, Italy, Mexico, Portugal, Sweden, Turkey

**Eurosemillas:** Poland, Turkey, China, Chile, Japan, Angola, USA

**Farmbiocontrol:** Chile

**Genetadi:** Mexico

**Genetrix:** Sweden

**Genhelix:** Japan

**Grifols:** Czech Republic, Germany, Argentina, Australia, Mexico, Singapore, Brazil, Chile, Slovakia, USA, France, Malaysia, Thailand, Italy, Japan, Poland, Portugal, UK

**Farmasierra Group:** Portugal

**Integromics:** USA

**Intelligent Pharma:** Germany

**Laboratorios Calier:** Portugal, Italy, Poland, Argentina, Brazil, Colombia, Mexico, Uruguay, Venezuela, Morocco

**Laboratorios Leti:** Germany, Portugal

**Neocodex:** USA

**Neuron bph:** USA

**Neuroscience Technologies:** UK

**Noray Bio:** Italy, France

**Pharmamar:** USA

**Probelte:** Mexico, Dominican Republic, Brazil, Poland, Jordan

**Progenika:** USA, Mexico, United Arab Emirates, UK

**TPRO:** China, Argentina, Brazil

**Thrombotargets:** USA


**Solutex:** USA



## International alliances

International alliances represent one of the most important aspects of the internationalisation of biotech companies. Through these alliances, companies and institutions minimise risk and gain easier access to resources, knowledge and new technologies.


In 2010, 29 ASEBIO companies and institutions (up 32% on 2009) entered into 48 international alliances, for a 20% increase on the previous year's figure. This statistic takes into account any type of formal agreement between at least one Spanish biotech company or institution and any other international entity, where this agreement entails an explicit commitment to secure shared objectives (R&D, production, sales, etc.).



**Chart 11:** Number of international alliances entered into by Spanish biotechnology companies/institutions (ASEBIO members) from 2005 to 2010

The bulk of these alliances were entered into with companies/institutions from the EU (54%) and the USA (17%), followed by Latin America (14%), Asia (13%) and, for the first time, Africa (2%).

A total of 92% of alliances were sought by companies from Catalonia (40%), Madrid (21%), Andalusia (19%) and Valencia (12%). Basque Country companies accounted for 6% of alliances, while companies based in the Balearic Islands represented 2%.



**Chart 12:** Geographic breakdown of international alliances entered into by Spanish biotechnology companies/institutions (ASEBIO members) from 2005 to 2010

# A.1.

Who is who?  
Business Partners

asebio





### 3P Biopharmaceuticals

• **Contact:** Dámaso Molero. General Manager • **Phone:** 34 948346480

• [dmolero@3pbio.com](mailto:dmolero@3pbio.com) • <http://www.3pbio.com>

• **Short description:** To offer comprehensive products and services of high quality and added value to our customers, satisfy our investment partners, and achieve the well-being of our employees. • **Products:** Monoclonal antibodies. Biosimilars. Human cells culture. Cell therapy and gene therapy. Protein expression systems and other process. Stability trials. Analytical developments. • **Interest areas:** Enterprises with a pipeline that needs a CMO as 3P. High technology partners that could implement 3P capabilities. Specific financing for specific projects. Industrial GMP facility of cell therapy. Industrial GMP facility of grub insect technology.



### AB Biotics S.A.

• **Contact:** Miquel A. Bonachera. CFO • **Phone:** 34 902903844

• [miquel@ab-biotics.com](mailto:miquel@ab-biotics.com) • <http://www.ab-biotics.com/> • **Description:** AB-Biotics has four business divisions: R+D PARTNERING offers the pharmaceutical and food industries the comprehensive management of research projects.

FUNCTIONAL INGREDIENTES develops probiotics and other nutraceuticals for the pharmaceutical and food sectors. Among them AB-FORTIS (cognitive development of children) AB-LIFE (improvement of cardiovascular health)

and AB-I3.1 (a probiotic for IBD/IBS).

AB-GENOTYPING develops genetic analyses for conducting pharmacogenetic studies. One of them is Neurofarmagen, already in the market. It is a DNA chip that enables the assessment of the patient's predisposition to respond to the drugs most widely used in treating depression, schizophrenia, bipolar disorders or epilepsy.

AB THERAPEUTICS is a subsidiary for discovering and developing new drugs based on Membrane Lipid Therapy. A drug for treating lung and pancreatic cancer is already in preclinical development.

• **Interest areas for futures collaborations/alliances:** In developing biotechnological products for human health. Our main objectives are functional genomics and nutraceuticals. We are always open to set up synergic partnerships with other companies in order to jointly develop new solutions.



### ABBOTT LABORATORIES, S.A.

• **Phone:** 34 913375200 • <http://www.abbott.es>

• **Description:** All that concerning or linked to pharmaceutical products, nutritional, diagnostic, molecular diagnostic, vascular devices, diabetes, optics.

Import, buying and selling, export, manufacture, production, transformation, operation, distribution, and marketing retail of any type of raw materials, products and chemical preparations, diagnostic products, veterinary products, biological products, pharmaceutical products, including any pharmaceutical specialty, foodstuffs products, dietary products, cosmetic products, hospital specialty products, produced or semi produced, and others in general, concerning healthcare.

Please, see our web: [www.abbott.es](http://www.abbott.es).

### ABENGOA BIOENERGIA

### Abengoa bioenergía

• **Phone:** 34 91 319 70 70 • [abengoabioenergy@abengoa.com](mailto:abengoabioenergy@abengoa.com)

• **Description:** Abengoa Bioenergy is a biotechnological company that contributes to sustainable development through the production of cheap sugars from starch and sugarcane. By means of fermentative processes that make possible a net reduction of contaminating emissions, Abengoa Bioenergy currently places on the market transportation fuels obtained from renewable resources. • **Mission:** Abengoa Bioenergy is a leader in the development of new technologies for the production of biofuels and other bioproducts through biotechnology and sustainability of raw materials, thus devoting a large amount of resources to research work. The activities of the company are included in the following main areas: - Procurement of raw material: Abengoa Bioenergía has managed to acquire great experience in procurement and appropriate logistical handling of raw materials, thus ensuring the supply of all plants of the business group. - Production: Bioethanol is produced in the plants of Europe and United States from cereal grains. As a co-product, the so-called DDGS, whose high protein content makes it suitable as livestock feed, is obtained. - Trading: AB Trading, devoted to the worldwide trading and export of our products, owns offices in Rotterdam (The Netherlands), St. Louis (USA) and São Paulo (Brazil). - New technologies: Abengoa Bioenergy in-house engineers and scientists, working together with research centers, universities and other industrial partners, develop innovative processes to increase ethanol yield from starch, improve quality of co-products and develop the technology of lignocellulosic biomass for production of bioethanol and other bioproducts through biotechnology. As a part of its business strategy, it develops and registers the Company's intellectual property rights in order to provide technology to third- parties under management agreements.



### Advancell Advanced In Vitro Cell Technologies, S.A.

- **Contact:** Dr. Kenneth Weissmahr. CEO
- **Phone:** 34 934034545
- [advancell@advancell.net](mailto:advancell@advancell.net)
- <http://www.advancell.net>
- **Description:** Advancell has two business units. Advancell Nanosystems is the R&D unit where we develop pre-clinical opportunities based on our proprietary nanomedicine technology which may enhance bioavailability or open previously unattainable delivery routes and possibly new indications for certain drug products. Advancell Therapeutics is the clinical development unit. Currently, Advancell has the following programs in clinical development
  - Nanomedicines for the use in psoriasis (licensed to ISDIN)
  - Acadra (Acadesina) Chronic lymphocytic leukaemia and multiple myeloma
  - Topical treatment of hand foot syndrome (ATH008),
  - An oral treatment for multiple sclerosis (ATH012)
  - Ciclostopic-Vet for the treatment of canine atopic dermatitis
- In addition, we pursue a series of preclinical opportunities.
- The business unit that develops and commercializes in vitro cellular models has been spun out into a new company called Readycell S.L.
- **Interest areas:** Collaborations with the objective to apply the nanosystem technology to change or enhance the administration of drugs in various administration routes (dermal, oral or nasal). In-licensing of preclinical programs in oncology, dermatology or CNS.



### Alexion Pharma Spain SL

- **Contact:** Jordi Casals. General Manager
- **Phone:** 34 932723005
- [casalsj@alxn.com](mailto:casalsj@alxn.com) • <http://www.alxn.com>
- **Short description:** Pharmaceutical product development and commercialization.
- **Products:** Humanized monoclonal antibody for the treatment of the Paroxistic Nocturnal Hemoglobinuria
- **Interest areas:** Biotechnology applied to general medicine Innovative drugs Orfan drugs commercialization in rare diseases.



### ALGAENERGY, S.A.

- **Contact:** Augusto Rodríguez-Villa. President
- **Phone:** 34 914902020
- [info@algaenergy.es](mailto:info@algaenergy.es) • <http://www.algaenergy.es>

• **Description:** ALGAENERGY, founded in 2007, is a technology based company working in the microalgae biotechnology sector. It has been promoted and is managed by a group of entrepreneurs and scientists with solid financial backing and extensive experience. The company is backed by IBERDROLA, world leader in renewable energy, and Spain's largest oil company REPSOL, as shareholders and technology partners.

With substantial R&D programmes, ALGAENERGY is linked to some of the most recognised international microalgae research centres and universities. ALGAENERGY's mission also includes the exploitation of the enormous talent and ability available in Spain within this area of science and expertise.

ALGAENERGY is already selling products from microalgae for aquaculture, under its brand name ALGAEPISCIS, and is also investigating the application of microalgae in pharmaceuticals, nutraceuticals, cosmetics and animal feed.

The company's ultimate goal is the production of biofuels from certain microalgae and cyanobacteria in a commercially viable way, promising alternative as its production may use waste water, brackish or marine, does not compete with agricultural land, production is high and sustainable and its main nutrient is CO<sub>2</sub> thus contributing to improving the environment.



### Allinky Biopharma

- **Contact:** Miguel Vega. CEO
- **Mobile Phone:** 34 618060829
- [lab@allinky.com](mailto:lab@allinky.com) • <http://www.allinky.com>

• **Short description:** Allinky Biopharma is focused on the discovery and development of small molecule drugs for the treatment of chronic inflammatory conditions, age-related degenerative diseases and cancer

• **Services:** Scientific and clinical research have shown that sustained oxidative stress, chronic inflammatory condition and progression cell missignalling are key factors in diseases such as Alzheimer's, ictus, rheumatoid arthritis, osteoarthritis, diabetes type II, atherosclerosis and certain types of cancer. Allinky develops novel therapeutics capable of modulating abnormal cell-molecular signals behind these diseases and thus contributing to restore normal cell-gene expression. Therefore, Allinky seeks to become a well-known player in the application of molecular-based medicine to fight prevalent diseases.



### Alma Consulting Group España

- **Contact:** Marta Orueta/Juan Antonio Costa. Marketing and Communication Responsible / Sales and Marketing Manager
- **Phone:** 34 915750301

• [morueta@almacg.com](mailto:morueta@almacg.com) • [jacosta@almacg.com](mailto:jacosta@almacg.com) • <http://www.almacg.es>

• **Description:** Our mission is to identify and obtain financing and savings for our customers.

We contribute to our clients competitiveness through measurable actions.

Professionals of ALMA Consulting Group work day by day to boost your growth through Innovation, providing the resources you need to finance your Research and Development potential, with a constant commitment for optimisation and security.

• **Products:** Areas of expertise: Innovation Financing. Property Tax. Overhead Expenses: telecoms, electricity, office cleaning, travels, etc.

• **Interest areas:** We create a long-term partnership with our customers in order to provide an outstanding support to improve their results.



## Amgen, S.A.

- **Contact:** Juan Carlos Esteban. Corporate Communication
- **Phone:** 34 936001900

• [jesteban@amgen.com](mailto:jesteban@amgen.com) • <http://www.amgen.es>

• **Short description:** To serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives.

• **Products:** Oncology and hematology treatments. Amgen is developing research programs in nephrology, hematology, oncology, inflammatory diseases, metabolism and neuroscience.



## Araclon Biotech, S.L.

- **Contact:** Guillermo de Vilchez Lafuente. Managing Director
- **Phone:** 34 976796562 • [gdevilchez@araclon.com](mailto:gdevilchez@araclon.com) • <http://www.araclon.com/>
- **Description:** Araclon Biotech is a private company devoted to research and development of immunotherapies and diagnostic methods used in the treatment of degenerative diseases. Currently focuses its efforts on Alzheimer's Disease, working on the validation and global commercialization of a diagnostic blood test kit and on the development of an effective immunotherapy.

In the field of Alzheimer's Disease:

Diagnosis: ABtest ®, blood test that determines beta-amyloid 40 and 42 peptide blood levels, which Araclon Biotech provides as an in-house service using their own kits (ABtest40 and ABtest42).

Therapy: Treatment with an active immunotherapy, entering clinical trials Phase I in 2011, with two different formulations.

• **Interest areas:** Araclon is open to proposals for basic and clinical research related to the following research lines already in development: Diagnosis of Alzheimer's Disease. Therapy for Alzheimer's Disease. Development of a Predictive kit for Alzheimer's Disease. Development of therapy for Parkinson's Disease.



## Archivel Farma, S.L.

- **Contact:** José Luis Cabero. Chief Executive Officer
- **Phone:** 34 934972456 • [archivel@archivelfarma.com](mailto:archivel@archivelfarma.com) • <http://www.archivelfarma.com>
- **Short description:** Discovery and initial clinical development of novel pharmaceutical agents of biological nature.
- **Products:** RUTI®, poly-antigenic vaccine made of fragments from Mycobacterium tuberculosis, detoxified, and formulated with liposomes. RUTI® is in phase II of clinical development for the prevention of active tuberculosis in

individuals with latent tuberculosis infection (therapeutic use). RUTI® is as well under evaluation for its use in the treatment of active tuberculosis and in other therapeutic areas.

• **Interest areas:** Prevention and treatment of tuberculosis with biological agents. Diseases or pathological conditions that could benefit from immunomodulatory treatments.



## Arquebio

- **Contact:** Jaume Mir Ph.D. CEO
- **Phone:** 34 935868926 • [jaume.mir@arquebio.com](mailto:jaume.mir@arquebio.com) • <http://www.arquebio.com>

• **Description:** ARQUEBIO S.L. was created in 2007 by a highly experienced team in industrial life-sciences and chemistry with great R&D+i network. The company offers alternatives to industrial chemical synthesis processes through developing bioprocesses based on microbial fermentation. Own research and contract research and a collaborative approach allows offering state-of-the-art knowledge and profitable technology transfer to industrial customers.

• **Products:** Chem to Biotech (C2B). C2B implies the substitution or modification of traditional chemical synthesis reactions by biotechnological approaches, which comprise either the use of wild type and recombinant bacteria, yeasts and molds, or their products, such as enzymes.

Nanotechnology for Biomedicine (N4B). N4B takes profit of the same technological platform to obtaining products by fermentation (recombinant proteins and polymers) and develop delivery systems for drugs (Drug Carriers) and nucleic acids (Gene Therapy). These Delivery Systems can improve efficacy and decrease secondary effects in Oncology, Neurodegenerative diseases and other therapeutic fields.

• **Interest areas:** Chemical, cosmetic, pharmacy, biotechnological and veterinary companies interested into introducing biotransformations in their manufacturing processes or interested in the evaluation and development of new approaches based on products obtained by microbial fermentation. ARQUEBIO collaborates with private and public research groups.



## Bayer BioScience N.V.

- **Contact:** Maica Martinez. Head of BioScience Records
- **Phone:** 32 92430468

- [maica.martinez@bayercropscience.com](mailto:maica.martinez@bayercropscience.com) • <http://www.bayercropscience.com>
- **Short description:** Bayer Bioscience N.V. is one of the main biotech innovation centres of Bayer CropScience AG, a subgroup of Bayer AG. The objective of the excellence centre is to integrate plant biotech research with the business demands of BayerBioscience to optimise innovating processes in a responsible and sustainable way. Drawing up crop management solutions (pest and weed control), researchers use genetic engineering to discover new features.
- **Products:** Patents, know how. Crops of high agronomic interest, with new features applied to modern crossing techniques.
- **Interest areas:** Agriculture, Environment-Biotechnology.



## Biobide, S.L.

- **Contact:** Idoia Ruiz de Azua. General Manager
- **Phone:** 34 943309360 • [ruizdeazua@biobide.es](mailto:ruizdeazua@biobide.es) • <http://www.biobide.es>
- **Description:** Biobide is a biotech company that aims to help our customers worldwide developing

taylor-made solutions to maximize R+D productivity and minimizing risks in the Drug Discovery process, integrating zebrafish animal model with innovative tools, adding value to their R+D+i mainly in the preclinical area (toxicology, safety and efficacy).

- **Products:** Capabilities for taylor-made solutions 1 Target validation 2 Transgenesis and disease model generation 3 Customized assay 3.1 TOXICITY: \* Specific toxicity Assays: \* Cardiotoxicity: Cardiotox assay \* Teratogenesis: Teratox assay \* Ototoxicity: Ototox assay \* Hepatotoxicity: Hepatotox assay \* General toxicity Assays: Acutetox assay 3.2 EFFICACY: \* Oncology: Angiogenesis inhibition assay \* CNS/Neurodegeneratives: Alzheimer assays
- **Interest areas:** Collaboration agreement with pharmaceutical and biotechnology companies with the aim of developing assays, increasing its value by means of this synergy collaboration. Company policy consists on setting up agreements with agents that possess quality research capacity and undertake applied research projects complementary to our company's activities, maximizing therefore the investment on all fronts.



## Bioftalmik

- **Contact:** Jon Careaga. Executive Director
- **Phone:** 34 944.069.659 • [jon.careaga@bioftalmik.com](mailto:jon.careaga@bioftalmik.com) • <http://www.bioftalmik.com>

- **Short description:** Our main objective is to design and develop diagnostic, prognostic and therapeutic systems for eye diseases and Bio-devices for ophthalmic surgery.
- **Services:** Integral R&D platform Diagnostic tests Clinical trials
- **Interest areas:** Our strategy clearly promotes scientific, technical and clinical collaboration and all its manifestations as the most effective ways to innovate. Our main areas of interest are: Ophthalmology, therapy, diagnostic, prognostic, cell culture, molecular biology, proteins, drug development and drug delivery.



## Biogen Idec Ibérica, S.L.

- **Contact:** Guido Decap Carrasco. VP & Managing Director
- **Phone:** 34 91 310 7110 • [guido.decap@biogenidec.com](mailto:guido.decap@biogenidec.com) • <http://www.biogenidec.es>
- **Mission:** We create new standards of care in neurology, oncology and immunology through our pioneering research, our global development, manufacturing and commercial capabilities.

• **Products:** With our stated mission to create new standards of care for unmet medical needs, Biogen Idec is focused on five therapeutic areas: Neurology, Immunology, Oncology, Cardiopulmonary and Hemophilia. These are areas in which we have both proven expertise and products in our pipeline that we believe can lead to first-in-class or best-in-class molecules. Within each area, we have selected targets based on both biology and the pathophysiology of disease. TYSABRI® (natalizumab) is a treatment approved for relapsing forms of MS in the United States and relapsing-remitting MS in the European Union. AVONEX® (Interferon beta-1a) has the most treatment experience for relapsing forms of MS worldwide, with more than 135,000 patients on therapy. It is used worldwide as a treatment for relapsing forms of MS to slow the progression of disability and reduce relapses. • **Interest areas:** At Biogen Idec, we believe strongly in the value of successful partnerships, and we do everything we can to make them work. If your company is in the later stages of development, Biogen Idec can provide a wealth of resources to help successfully commercialize your product. Our approach to partnerships is driven by two core principles that promote success: respect and flexibility. We are interested in partnerships in our core therapeutic areas, which include neurology, oncology and immunology. In addition, we welcome products in acute care, including cardiovascular, hemophilia, infectious disease, and other products used in a hospital environment. We also have active programs in hemophilia research and development. In fact, we are open to partnerships in additional therapeutic areas that lend themselves to a specialty biopharma business model.



### Biokit, S.A.

- **Contact:** Pau Planas. Quality Assurance Manager
- **Phone:** 34 93 860 90 00

- [pau.planas@biokit.com](mailto:pau.planas@biokit.com) • <http://www.biokit.com>
- **Short description:** Development, production and commercialization of immunoassays for the clinical diagnostics (IVD) market.
- **Products:** Serology reagents for the diagnosis of infectious diseases and for the detection of plasma proteins. Manual assays (latex agglutination, hemoagglutination, immunochromatography), ELISA assays and assays for automatic platforms (immunoturbidimetry and chemiluminescence) OEM services: Contract development and manufacturing of immunoassays for clinical chemistry, immunochemistry and coagulation applications. Raw materials: Polyclonal and monoclonal antibodies. High-quality natural and recombinant antigens.
- **Interest areas:** New clinical biomarkers with high diagnostics potential, apt to be detected through the use of high sensitivity immunoassays. OEM immunoassay opportunities.



### BioMarin Europe Ltd. Sucursal en España

- **Contact:** Felis Iglesias. Area Director Iberia, Israel, UK and Ireland

- **Phone:** 34 800 808 508
- [figlesias@bmrn.com](mailto:figlesias@bmrn.com) • [www.biomin.com](http://www.biomin.com)
- **Description:** BioMarin seeks to develop product candidates that: Address currently unmet medical needs. Suggest a clear-cut development profile. Provide an opportunity to be first-to-market.
- **Products:** Naglazyme. Aldurazyme. Kuvan.
- **Interest areas:** Metabolic Diseases. Enzyme Replacement Therapies.



### BioMaslinic, S.L.

- **Contact:** José Prados Osuna. CEO
- **Phone:** 34 958750981
- [biomaslinic@biomaslinic.es](mailto:biomaslinic@biomaslinic.es)

- **Short description:** Manufacture and supplier, acknowledgement and applications of Maslinic Acid and Hidroxitirosol.
- **Products:** Animal growth promoter, nutraceuticals, functional foods and antiinflammatory indications.
- **Interest areas:** Maslinic acid has demonstrated a high selective apoptotic capacity over tumoral cells, based in the description of its route of activity. The experiments in vivo have been developed having a great success. Now BioMaslinic S.L. is working about its potential pharmaceutical application. So collaboration is needed to carry on different studies along the different phases of investigation, and also alliances to advance its development and marketing.



### Biomedal, S.L.

- **Contact:** Ángel Cebolla Ramírez. General Manager
- **Phone:** 34 954081276
- [acebolla@biomedal.com](mailto:acebolla@biomedal.com) • <http://www.biomedal.com>

- **Description:** To develop new, innovating technologies for the progress of post- genomic research and the efficient industrial production of new biomolecules that are useful for society.  
The company develops its activities in two areas:  
Biomedal Life Science  
R&D contracts, DNA synthesis, peptide and protein production, antibodies, protein expression and purification systems, kits for molecular biology, affinity chromatography, strains, plasmids, etc.  
Biomedal Diagnostics  
Health related bioanalytic systems, detection of immunological diseases markers, food safety products such as Glutentox, and Oleotest, food analysis etc.



### Biomol-Informatics

- **Contact:** Dr .Paulino Gómez-Puertas. Scientific Advisor
- **Phone:** 34 647504634
- bioinfo@bioinfo.es • <http://www.biomol-informatics.com>
- **Short description:** BIOMOL-INFORMATICS offers consulting services on Bioinformatics in

areas of research, diagnostics and pharmaceutical industry. Located in the campus of the Autonomous University of Madrid, the company is specialist in Rational Drug Design using 3D computational simulation, Molecular Dynamics of macromolecules and Data Analysis of "Next-Generation DNA Sequencing (NGS)".

• **Services:** "In silico" analysis and prediction of new drugs activity on 3D models of proteins and in molecular dynamics techniques applied to docking of compounds. Data Analysis of "Next-Generation DNA Sequencing (NGS)": human genome, cancer-related mutations, hereditary illnesses

• **Interest areas:** "In silico" design of anti-obesity drugs. Molecular dynamics simulation of polymerization and depolymerization processes of bacterial septum protein FtsZ: "in silico" design of antimicrobials. Collaborative project 7FP - EU. Data Analysis of "Next-Generation DNA Sequencing (NGS)".



### BIONATURIS

- **Contact:** Victor Infante. CEO
- **Phone:** 34 856818424
- info@bionaturis.com • <http://www.bionaturis.com>
- **Short description:** BIONATURIS is a specialty biopharmaceutical company that develops

and manufactures a new generation of more affordable biopharmaceutical products by means of FLYLIFE. FLYLIFE is a revolutionary Plug&Play system for producing tailor-made biologics at industrial scale. The easiest and quickest way to manufacture local batches of new generation vaccines or antibodies.

• **Products:** Bionaturis is focused on clinical-stage developing of highly cost-effective biological APIs for unmet diseases, especially in the field of second generation vaccines for human and animal health.

• **Services:** Bionaturis acts as CDMO developing and manufacturing biological APIs by means of its FLYLIFE platform, in compliance with cGMP standards.

• **Interest areas:** Second generation vaccines; Virus-Like Particles; recombinant antigens; biological downstream; out-licensing of early stage -preclinical or phase I- leads; oral delivery systems for protein-based vaccines.



### Bionet Ingeniería

- **Contact:** Enrique López. Head of Chemical Engineering
- **Phone:** 34 902170704
- enrique.lopez@bionet.com • <http://www.bionet.com>
- **Short description:** To provide engineering services and turnkey construction of process package units for the biotech industry (fermentation, downstream, purification, isolation...).

Our commitment to our clients means that we offer an integrated service for the whole project life cycle; from lab to industrial facilities and process start up.

• **Products:** Lab to Market Engineering [L2M]. From process development at lab-scale we offer: Feasibility studies. Industrialization and scale-up studies. Turnkey construction of pilot plants. Pilot plant testing. Project management of biotech investments: Basic and detailed engineering. Project management or turnkey construction of industrial facilities. Commissioning and start up according to GMPs.

• **Interest areas:** Technology centres and R&D departments with new processes that want to add value to the Process Technology Package through a viability study, from an engineering point of view, considering existing / potential investors. New industrial investment projects and facilities that want to introduce a new process / product or that simply want to revamp an existing one. Technology centres that can collaborate in process optimization and troubleshooting.



### Bionure Farma, S.L.

- **Contact:** Alberto G. Zamora. CEO
- **Phone:** 34 931258607
- **Mobile Phone:** 34 620857779 • [info@bionure.com](mailto:info@bionure.com) • <http://www.bionure.com>
- **Description:** Spin-off from the Hospital Clinic of Barcelona-IDIBAPS and the CSIC that was born

in 2009 with. The aim of Bionure is developing neuroprotective drugs working as neurotrophins agonists (such as NGF, BDNF, NT 3/4) by targeting their receptors. At present, there are no neuroprotective drugs in the market, so it represents a new approach for the treatment of brain and retina diseases using a new mechanism of action in a well known pathway avoiding high selectivity for preventing side effects and covering common pathways for neuroprotection. Neuroprotective activity in vitro and beneficial in vitro effects (in animal models for MS) have been already demonstrated from 9 molecules protected by 3 patents filed to the European Office and licensed to Bionure. From those molecules, G79 has been identified as the candidate for its development as neuroprotective therapy for MS, Glaucoma and other nervous system diseases. At present, Bionure has obtained in vitro and in vivo a proof of concept for treatment with G79 in models for MS, Glaucoma, Parkinson, and is currently completing studies for Alzheimer, Amyotrophic lateral sclerosis (ALS), Senile macular degeneration and Retinitis pigmentosa. The aims of Bionure are complete G79 preclinical development for indications of MS and Glaucoma and seek agreements with other companies to license or co-develop G79 for indications of other neurodegenerative diseases.



### Biopolis, S.L.

- **Contact:** Daniel Ramón Vidal. Director General
- **Phone:** 34 963160299
- [biopolis@biopolis.es](mailto:biopolis@biopolis.es) • <http://www.biopolis.es>
- **Short description:** The main objectives of Biopolis S.L. are to design, produce and purify microorganisms

(bacteria, yeasts and filamentous fungi), microbial metabolites: high-value by-products (enzymes, proteins and nucleic acids) following classical fermentation methods and metabolic engineering design.

- **Services:** Probiotic against *H. pylori* infection; use of *C. elegans* for Alzheimer candidate screening, use of *C. elegans* for obesity, diabetes, aging, microbial infection testing; custom design and selection of microbial strains/valuable biochemical compounds, process design, development and production of microorganisms and derivatives, production of new generation biofuels and biopolymers, metabolomic analysis.

- **Interest areas:** Biopolis S.L. offers its services both to industries, such as the food and feed sector, agrochemical, chemistry, pharmaceutical and environment, as well as to public and private research centers.

Finding customers and collaborators: for contract manufacturing of microbial strains or specific industrial-microbiology-derived compounds. for contract R&D using proprietary biological model (*C. elegans*), ultrasequencing (454 Roche), metabolomics, nutrigenomics and nutrigenetics tools.



### Biosearch S.A.

- **Contact:** Luis Enrique García Ayuso. Quality and Research Manager
- **Phone:** 34 913802973
- [luisegarcia@biosearchlife.com](mailto:luisegarcia@biosearchlife.com) • <http://www.biosearchlife.com>
- **Short description:** Company dedicated to research, development and commercialization of new products based on natural ingredients with health benefits

- **Products:** Vegetable, lipid and probiotic extracts

Exclusive product development

Technical and legal consultants

Regulatory affairs

Stability studies

- **Interest areas:** Development of new bio active ingredients based on vegetable, lipid and probiotics extracts and their application in the pharmaceutical, food and cosmetic industries.



## Bioserentia

- **Contact:** Jorge Arenas-Vidal. Director
- **Phone:** 34 914311970 • jarenas@bioserentia.com • <http://www.bioserentia.com>
- **Short description:** Partner with companies, entrepreneurs, investors, governments to create

and accelerate Ventures in Life Sciences.

- **Services:** Corporate Strategy, Strategic Investments in Life Sciences R&D Strategy and Management Fund Raising BioEntrepreneurship Platform BioBusiness Incubation & Acceleration Interim Management Commercial, Sales & Operational Support
- **Interest areas:** HEALTH: Oncology, Rheumatoid Arthritis, Wound Healing, Transplantation, Cellular Therapies, Vaccines, Pharmacogenomics, Nutrigenomics. Personalized Medicine, Convergent Technologies. ENERGY: biomass optimization, biorefineries strategy and implementation.



## Biot

- **Contact:** Agustín Lasserrot. General Director
- **Phone:** 34 958 750 618 • direccion@biot.es • <http://www.biot.es>
- **Short description:** BIOT is a Biotech Enterprise group focus on innovation and R&D in Microbiology.

Goals are achieved from the interaction between different BIOT Companies and Research Groups from Universities, Research Institutes and other Companies as well. BIOT develops reliable solutions, products and methodologies based on microorganisms in the areas of agro-food, environmental and bioenergy production.

- **Products:** Selected strains of high biotechnological interest for different industrial sectors: Probiotics. Biofuel producers: methane, ethanol and biodiesel. Bioplastic producers. Soil and water decontamination. Enzymes and biomolecules from microorganisms of high industrial interest. Genetic constructions for improving microbiological processes.
- **Services:** Selection, isolation, quantification and identification of microorganisms using biochemistry and genetics techniques. Genetic Engineering Service of microorganisms. Analysis of microbial communities in terrestrial and aquatic ecosystems. Design and conservation of microbiological resources and culture collections of biotechnological interest. Consulting and advice in the field of Microbiology. Innovation, R&D Project Performing and Management.
- **Interest areas:** Renewable energies production. Remainders. Biofuel production. Residual, industrial and urban water purification. Bioremediation. Functional food and nutrition-health  
New active biomolecules. Nourishing industry. Security and microbiological control. Projects of I+D+i in cooperation.



## Biotherapix Molecular Medicines S.L.U.

- **Contact:** Juan Sebastián Ruiz. Institutional Relations Director
- **Phone:** 34 918063089 • jsruiz@genetrix.es • <http://www.biotherapix.com>
- **Short description:** Biotherapix Molecular Medicines S.L.U. is a company belonging to Genetrix Group,

which specializes in generating high affinity biological molecules to treat inflammatory diseases. \*Programmes under way: - New generation of anti-inflammatory drugs - specifically chemokine receptor antagonists (Diakinas®). - Platform for generating and selecting (screening) human monoclonal antibodies for therapeutic and diagnostic purposes.

- **Interest areas:** Molecular therapy Protein biology Protein production and purification systems Development of therapeutic antibodies Inflammation Infectious diseases.



## Biotoools B&M Labs, S.A.

- **Contact:** Carmen Tomás- Verdura Alba. Chief Communications Officer
- **Phone:** 34 917100074 • ctomas@biotoools.eu • <http://www.biotoools.eu>
- **Description:** Research, development and manufacture of recombinant enzymes and other tools for molecular biology. Development of new technologies for molecular diagnostics and biomedical research. Comprehensive, fast, simple, robust, automatable and competitive diagnostic solutions, based on internationally patented proprietary technologies and reagents from the company.
- **Products:** Recombinant enzymes, nucleic acid purification systems and other reagents for molecular biology. Ready-to-use Molecular diagnostic Kits based on Gelification Technology (one tube-one reaction)
- **Services:** Services for design, stabilization and automation of nucleic acid amplification reactions. Services for the development of comprehensive automatable solutions for molecular diagnostics.
- **Interest areas:** Technology transfer: Transfer of Biotoools Gelification Technology for the stabilization in a single tube all necessary reagents to perform an amplification reaction. This technology has been licensed to the Brazilian Public Health System, and it has been implemented in Brazilian blood banks for the detection of HIV and HCV among blood donors.



## Bosques Naturales, S.A.

- **Contact:** Teresa Jiménez. Communication Manager
- **Phone:** 34 913604200
- [teresajimenez@bosquesnaturales.com](mailto:teresajimenez@bosquesnaturales.com)
- <http://www.bosquesnaturales.com>

• **Description:** Promotion and maintenance of fine wood forestry plantations. This activity has a triple function: Sustainability, Productivity and Innovation. Bosques Naturales is a company leading research and development which applies vegetal biotechnology and intensive agronomic techniques to its production processes. Its lines of research in forestry biotechnology are oriented to genetic characterization of vegetal material in order to improve the volume and quality of wood.

• **Products:** Plantations of high economic value trees using selected vegetal material which is reproduced "in vitro". The company has a Vegetal Tissue Growth Unit which provides its own germplasm bank.

• **Services:** Bosques Naturales covers all the growth and maintenance costs of the trees during the twenty or twenty-five years which their productive cycle lasts.



## BTI Biotechnology Institute

- **Contact:** Dr. Eduardo Anitua Aldecoa. Scientific Affairs Manager
- **Phone:** 34 945160652

- [eduardoanitua@eduardoanitua.com](mailto:eduardoanitua@eduardoanitua.com) • [www.bti-implant.es](http://www.bti-implant.es)
- [www.prgf.es](http://www.prgf.es) • [www.institutoeduardoanitua.com](http://www.institutoeduardoanitua.com)

• **Short description:** Research and development of new product, new materials and new processes for biological material obtaining through several technologies some of them related to Regenerative Therapies.

• **Products:** Design and manufacture of dental implants, prosthetic components and surgical instruments, Bioactivatable surface for implantology. Technology development for tissue regeneration using Plasma Rich in Growth Factors (PRGF). Educational material and courses development, and its diffusion. Diagnostic software

• **Interest areas:** Tissue engineering, bone regeneration, regenerative therapies.



## Canvax Biotech S.L.

- **Contact:** Elier Paz Rojas. Managing Director

- **Phone:** 34 957420870
- [e.paz@dominion.es](mailto:e.paz@dominion.es) • <http://www.dominion.es/index.html>
- **Short description:** The search for antigens for vaccines
- **Products:** Own technology for the identification of antigens inducing T CD4+ and CD8+ response.
- **Interest areas:** Vaccine sector, model animals for protection against infections



## Cellerix, S.A.

- **Contact:** Claudia Jimenez. Corporate Development Senior Director
- **Phone:** 34 918049264

- [info@cellerix.com](mailto:info@cellerix.com) • <http://www.cellerix.com>

• **Short description:** Cellerix aims to become the European leader of cell-based pharmaceutical products for the treatment of autoimmune diseases, the Company has already established a platform of expanded adult stem cells of adult origin and is now focusing on the development of an allogeneic platform of eASCs, comprising programs that contemplate local, intravenous and intranodal administration.

Allogeneic programs

Local Administration

Cx601\* - First indication: Complex fistula in Crohn's patient. Preparing clinical trial application Phase III

Systemic Administration

Cx611 - First indication: Rheumatoid Arthritis. Preparing clinical trial application phase I/IIa

• **Interest areas:** With these products, Cellerix aims to tap into much larger markets within the inflammatory and autoimmune disease areas and thereby fulfill its vision of becoming a leader in the cell therapy space and offer patients novel cell-based treatments for unmet medical conditions.



### Clave Mayor, S.A., S.G.E.C.R.

- **Contact:** Ricardo Pérez. Managing Director
- **Phone:** 34 948203960
- [perez@clavemayor.com](mailto:perez@clavemayor.com) • <http://www.clavemayor.com>
- **Short description:** CLAVE MAYOR, SA, S.G.E.C.R. is a Venture Capital Entities Management Company, registered in the National Securities Market in 2002. Clave Mayor's aim is to invest in key projects with proven capacity for growth and expansion, which have solid management teams.

capacity for growth and expansion, which have solid management teams.

- **Services:** Clave Mayor, using funds that it manages, has realized investment in biotechnology companies such as Lactest, Idifarma, Emy-salud, Vivotecnía Research Laboratories Ojerpharma, Vivia Biotech, Biomedical Developments Clavesuan and Bionostra. Clave Mayor is interested in evaluating investment opportunities in the health sciences and food industry fields, where it has vast experience.
- **Interest areas:** Projects in consolidated phases with solid proof of concept. Projects managed by solvent and involved teams Co-investment with other specialized funds. Development projects build-up and growth through acquisitions.



### Clean Biotec

- **Contact:** Nathalie Beaucourt. R&D Manager
- **Phone:** 34 941238261
- [clean@clean-biotec.com](mailto:clean@clean-biotec.com) • <http://www.clean-biotec.com>
- **Short description:** Find solutions to resolve environmental pollution problems using clean, sustainable and economical technologies Improve the natural regulation capacity of ecosystems to reduce environmental impacts New ways of natural and controlled systems for waste elimination and recycling.

and economical technologies Improve the natural regulation capacity of ecosystems to reduce environmental impacts New ways of natural and controlled systems for waste elimination and recycling.

- **Services:** Ecodiagnosics Environmental audit reports Waste assesment projects Paleobotanic studies Implantation and control of biomonitoring networks Phytoremediation and Bioremediation R & D biorremediation projects Restoration of degraded lands Reseach and improvement of new phyto and bioremediators Microorganism research from extreme environments to use in bioremediation and other biotechnological applications.
- **Interest areas:** Environmental microbiology Bioremediation Biomonitoring Metagenomics.



### CPQ Ingenieros S.L.

- **Contact:** Ricard Gené. Technical Manager
- **Phone:** 34 932478830
- [rgene@cpqingenieros.com](mailto:rgene@cpqingenieros.com) • <http://www.cpqingenieros.com>

- **Short description:** CPQPharma division's prime objective is to provide highly professional consultancy, process and detail engineering and supervision services for the industrial projects of pharmaceutical and biopharmaceutical companies.
- **Services:** Basic and detail engineering and supervision for pharmaceutical and biopharmaceutical companies. Pilot Plant design. Process and bioprocess scale-up. Cost Estimation of biopharmaceutical facilities.
- **Interest areas:** Pharmaceutical and Biopharmaceutical Industrial installations Cost Estimation of Biopharmaceutical Industrial Installations Pilot Plant Design Process and Bioprocess Scale-Up Industrial Biotechnology Industrial Nanotechnology.



### Digna Biotech, S.L.

- **Contact:** Pablo Ortiz Ceo
- **Phone:** 34 911852510 • [portiz@dignabiotech.com](mailto:portiz@dignabiotech.com) • <http://www.dignabiotech.com>

- **Description:** Digna Biotech is a biotechnological company dedicated to the development and exploitation of the research products generated by the Center of Applied Medical Research in Pamplona, one of the most important private biomedical research centers in Europe.  
RARE DISEASES: Escleroderma (morphea and systemic sclerosis): Disitertide (P144). Isquemia / Reperfusion in solid organ transplant: CT-1 (cytokine). Acute intermittent porphyria: Viral vector adeno-associated for the deficiency of porphobilinogen deaminase (PBGD)  
ONCOLOGY: Melanoma: P17 and Disitertide (P144). Actinic Queratosis: Disitertide (P144). Skin cancer: Disitertide (P144). Bone metastasis: P17. Therapeutic vaccine: EDA-HPVE7. Oncologic adjuvant: P17  
OFTALMOLOGY: Macular degeneration: P17 and Disitertide (P144)  
HEPATOLOGY: Hepatitis C: IFNa5. Hepatic resection: CT-1 (cytokine)  
NERVOUS CENTRAL SYSTEM: Multiple sclerosis: MTA (small molecule). Alzheimer: 4PBA (4-phenylbutyrate)  
Disitertide (P144): Dermal indications are licensed to ISDIN. CT-1: Hepatic indications are alliance to Biotecnol y Genentech. Porfiria Viral Vector: Licensed to AMT. Alliance with AMT to search and development for treatments based in viral vector for gene therapy.
- **Interest areas:** Therapeutic vaccines, oncology, nervous central system diseases.



### Diomune S.L.

- **Contact:** Carolina Egea. CEO • **Phone:** 34 918064656
- [cegea@diomune.com](mailto:cegea@diomune.com) • <http://www.diomune.com>

• **Short description:** Diomune is a biotech company specialized in research and development of new immunology treatments oriented to human and animal health areas in infectious, inflammatory and autoimmune diseases.

The three main lines of business of the company are to develop a veterinary drug to cure canine leishmaniasis, research and develop a drug to treat sepsis in humans and seek licensing agreements for the use of an innovative immunomodulatory compound as an adjuvant for vaccines.

- **Products:** Murine models of sepsis (LPS, E. coli, CLP), Leishmaniasis, models with and without adjuvant vaccine or with and without subsequent treatment, inflammatory models (rheumatoid arthritis, psoriasis, asthma, acute inflammation by carrageenan peritonitis by thioglycolate), Cancer colon associated with ulcerative models, metabolic syndrome and obesity, hepatic cirrhosis, and so on. Validations: Microbiological tests, determination of glucose, lactic acid, cell proliferation, apoptosis, cytokines in culture supernatant and serum, monitoring of cell populations by flow cytometry, antibody titers, study of the Th1/Th2 balance, and so on. Variety of cell types available.
- **Interest areas:** Our main interest for future collaboration focuses on the implementation of licensing agreements or joint ventures, with other companies with greater capacity than ours, to develop clinical trials for sepsis and septic shock in human phases with our drug (which has been shown excellent results in animal models). Also, we would like to contact other companies who develop and/or market vaccines that seek new adjuvants to enhance their action.



### EntreChem, S.L.

- **Contact:** Francisco Morís. Co-founder & CEO
- **Phone:** 34 985 259021
- [info@entrechem.com](mailto:info@entrechem.com) • <http://www.entrechem.com>

• **Short description:** Our objective is the discovery and development of bioactive new chemical entities (NCEs)

from microbial natural products. We generate novel analogs by combinatorial biosynthesis of the corresponding metabolic pathways, identify the most promising candidates and advanced the preclinical development until demonstration of efficacy in vivo.

• **Products:** EntreChem offers genetic engineering for identification and manipulation of metabolic pathways from bacterial natural products of interest in the pharmaceutical (antibiotics, antitumorals, antifungals) and agro (insecticides, herbicides) sectors. EntreChem offers enantiopure products for medicinal chemistry and services of applied biocatalysis, as well as custom synthesis of optically pure compounds.

• **Interest areas:** Discovery and development of new drugs from natural products by genetic engineering and biocatalysis. Antibiotic and antitumoral activity assays (cellular and biochemical), target identification. Early preclinical in vivo studies (efficacy, PK). Bioprocess scale-up.



### ERA Biotech

- **Contact:** Sr. Lieven De Smedt. Director General
- **Phone:** 34 934034773
- [info@erabiotech.com](mailto:info@erabiotech.com) • <http://www.erabiotech.com/>



### Era7 Information Technologies, S.L.

- **Contact:** Eduardo Pareja. Director General
- **Phone:** 34 958750629
- [epareja@era7.com](mailto:epareja@era7.com) • <http://www.era7.com>

• **Short description:** To help biotech companies and organizations in the biomedical field to take advantage of Information Technologies for a better information and knowledge management. With this objective in mind we design and provide advanced software solutions specially based on Internet technologies.

• **Products:** Palinsight Pro: software for DNA palindromicity analysis and representation. Livera7 : Software specially designed to manage and held real time virtual Congresses and workshops.

• **Services:** Services of Knowledge Expression. Services of custom software development of Web applications, intranets, Web platforms and bioinformatics workflows automation. Bioinformatics and biosciences consultancy services.

• **Interest areas:** Bioinformatics software development. Participation in R&D and innovation projects including participation in the EU VII Framework Program Agreements for marketing and distribution of our services and products.



## Esteve

• **Contact:** Dr. Eduard Valentí. R&D Operations Manager

• **Phone:** 34 934466000 • [evalenti@esteve.es](mailto:evalenti@esteve.es) • <http://www.esteve.com>

• **Short description:** ESTEVE is a private, fully integrated International Group that pursues innovation and excellence in the pharmaceutical-chemical industry, while maintaining its dedication to the promotion of health for the benefit of society.

R&D: ESTEVE invests significantly in R&D, focused in analgesia. Its lead program is a Sigma-1 receptor antagonist for neuropathic pain.

• **Products:** ESTEVE is a diversified company marketing a wide range of ethical and OTC pharmaceutical products, vaccines, generics, products for veterinary use and it manufactures APIs.

ESTEVE has also established strategic alliances, ISDIN for dermatological products and ESTEVE-TEIJIN-HEALTHCARE in home respiratory therapy.

• **Interest areas:** ESTEVE is open to evaluating new opportunities for collaboration, especially in the area of analgesia.



## EuroGalenus Executive Search

• **Contact:** Luis Truchado. Partner-Director

• **Phone:** 34 913505556 / 7414 • [luis@eurogalenus.com](mailto:luis@eurogalenus.com) • <http://www.eurogalenus.com>

• **Short description:** Contribute to the identification and development of the best executives in the Biotechnology field.

• **Services:** Since 1992, recruitment of Board positions, non-executive Directors and senior Scientists.

Experience in Biotechnology, Diagnostics, Devices, Electromedicine, Pharmaceuticals, Nutrition, Cosmetics, Veterinary, and their Service companies.

• **Interest areas:** Recruitment, training, HR consultancy.



## Eurosemillas, S.A.

• **Contact:** José Pellicer. Development Manager

• **Phone:** 34 957421732 • [eurosemillas@eurosemillas.com](mailto:eurosemillas@eurosemillas.com) • <http://www.eurosemillas.com>

• **Short description:** To be a company of reference in the farming world, committed to agricultural develop-

ment in the geographical areas where it is present.

• **Products:** Select seeds CottonGrain: cotton grain animal feed Cotton fibre Oleaginous oils Development of licences for various plants: Fruit trees. Strawberry. Citrus fruits. Raspberry Others: avocado pears, asparagus, etc.

• **Services:** Farming news portal <http://terraagraria.es> Development of an electronic commerce platform.

• **Interest areas:** Select seeds Genetic improvement Biotechnology Development of plant varieties Farming portal Extraction of vegetable oils and cotton fibre.



## Farm Biocontrol, S.L.

• **Contact:** Rafael Arlegui. Manager Director

• **Phone:** 34 976660114 • [internacional@farmbiocontrol.com](mailto:internacional@farmbiocontrol.com) • [r.arlegui@farmbiocontrol.com](mailto:r.arlegui@farmbiocontrol.com)

• <http://www.farmbiocontrol.com/>

• **Short description:** The commitment between Farm Biocontrol and the R+D inside the environmental frame, has leads us to be part of CDTI programme which is promoted by the Industry and Commerce Ministry of the Spanish Government. Farm Biocontrol offers complete services of consultancy, assistance and implementation of integral plans in order to reach a biosanitary control in livestock farms. Our mission is provided with the highest biosafety level to pig, cattle, poultry and fish farms. The enormous scientific team who supports us, allows to reach this aim focusing our efforts fundamentally in two work areas: - Research, development, production and marketing of new products such as pesticides, biological disinfectants, products for the animal hygiene, as well as procedures of application. Applicable to waters, atmospheres, surfaces or directly over animals. - Development of integral and personalized programmes of biosafety in livestock farms. Our entailment with the academic World, has leaded us to be accredited as an European Approved Training Centre in order to train to a many professionals linked to the live stocking, agro-feeding and environmental sector.

• **Products:** Expert Consultancy and elaboration of reports and Action Plans Systems to the slurry treatment Systems to the gas emission reduction Pest Control Waters and Effluents Control Salmonella Control Laboratory Analysis Training for technicians, managers and staff Hazard Identification and Analysis of Critical Control Points

• **Interest areas:** Biotechnology Biosafety and hygiene Food traceability Agriculture Farms disinfection Water treatment Food Industry Fish farms.



### Fina Biotech, S.L.

- **Contact:** José-Cándido Arochena Amestoy. Director General
- **Phone:** 34 915129599
- [jc\\_arochena@finabiotech.es](mailto:jc_arochena@finabiotech.es) • <http://www.finabiotech.es/>



### Gendiag

- **Contact:** Margarita Garrido. Associate CEO
- **Phone:** 34 935093233
- [margarita.garrido@gendiag.com](mailto:margarita.garrido@gendiag.com) • <http://www.gendiag.com>
- **Short description:** GENDIAG is a research-driven biotech which aims to facilitate the personalized medicine by offering to the society new genetic diagnostic tools and new therapeutic targets, which can help to the development of innovative drugs, in a worldwide commercialization basis.
- **Products:** Gendiag's current development status of the projects: CardioinCode®), DNA-Chip will analyze more than 111 genes to determine the risk to suffer a cardiovascular event in patients with moderate risk and will identify the altered signaling pathways with cardiovascular significance for the patient. Sudd inCode®) DNA-Chip will determine the risk to suffer sudden death identifying more than 50 genes associated to arrhythmic congenital syndrome and cardiomyopathys. Trombo inCode® DNA-Chip for genotyping polymorphisms in genes involved in hereditary thrombophilia. This tool will incorporate the genetic tests that are currently performed individually and sequentially in order to find a genetic alteration. Hemato inCode® DNA-Chip will determine the progression of chronic lymphocytic leukemia and assists in treatment selection.
- **Interest areas:** GENDIAG creates alliances with investigators, research institutes, biotech and or pharmaceutical companies for the development of their project on a faster and efficient manner. GENDIAG wants to involucrate to the investigator in the development of the project and to share with him the benefits of the marketing when the idea turn into product.



### GENETADI Biotech

- **Contact:** José Luis Castrillo. CEO
- **Phone:** 34 944044343
- [info@genetadi.com](mailto:info@genetadi.com) • <http://www.genetadi.com>
- **Short description:** Genetadi Biotech is a company that develops new human genetic diagnosis kits specialized in the gynecology, pediatric and oncology biomedical sectors. Our company is integrating its projects of research and development in Systems Biology applying the most modern techniques developed after human genome sequencing.
- **Products:** AMNIOCHIP & NEONATAL-ONE
- **Services:** Prenatal and neonatal testing by aCGH microarrays Cytogenetic and molecular genetics services Analytical metabolic services by mass spectrometry (MS/MS). Human genomic NGS services
- **Interest areas:** Nanodiagnostics Single-molecule DNA sequencing Human genomic analysis (Bioinformatics).



### Genetrix, S.L.

- **Contact:** Juan Sebastián Ruiz. Institutional Relations Director
- **Phone:** 34 91 8063089
- [jsruiz@genetrix.es](mailto:jsruiz@genetrix.es) • <http://www.genetrix.es>
- **Short description:** Genetrix, created to promote entrepreneurial leaders in the biotechnology sector, is a group of companies aimed at generating value from using the results of academic and clinical research for the benefit of society.
- **Services:** Genetrix is constantly working to bring together the outcomes arising from different scientific disciplines, by setting up and maintaining collaborations of a varied nature with public research centres, technological centres, public and private hospitals and pharmaceutical and biotech enterprises. This collaborative spirit is one of the features that most identifies the Genetrix Group s and its has proven to be of great value in making this ambitious business project a reality. The Group is working on the creation of biotech initiatives assessing, designing and executing business plans in the life sciences field. The rapid evolution of the Genetrix Group is the direct result of the excellent quality of the work carried out by its professionals and the special concept held by its development team of the biotech business. The group s speed of development is also underpinned by the selection of staff from a scientific and business background, in the keeping up of the links and collaboration with a variety of groups and the appointment of professionals of the highest level onto its management team.
- **Interest areas:** Biotechnology Life Sciences Scientific applications for medical purposes Investment in biotechnology.



### Genomica, S.A.U.

- **Contact:** Rosario Cospedal. General Manager
- **Phone:** 34 916748990
- [rcospedal@genomica.es](mailto:rcospedal@genomica.es) • <http://www.genomica.es>

• **Short description:** GENOMICA, S.A.U., a company specialised in molecular diagnostics. Genómica is the only Spanish company which provides human diagnostic systems based on molecular biology and DNA microchips for clinical medicine. Molecular diagnostics, through the design, development, automation and commercialisation of in vitro diagnostic systems under CLART®, Clinical Array Technology, brand.

Its development lines range from diagnosis of viral and bacterial diseases through to the detection of areas of the human genome associated with factors that determine the response to therapies.

Analysis of DNA for legal and forensic medicine.

Technology transfer: turnkey installation of genetic fingerprinting laboratories

• **Interest areas:** GENOMICA sells its products in 30 countries worldwide. It is currently in the process of expanding to markets in the Middle East and Eastern Europe.

• **In-licensing:** Molecular diagnostic systems in oncology. New technologies in molecular diagnostics.

• **Out-licensing:** Technology and training in DNA profiling.



### Genzyme, S.L.

- **Contact:** Fernando Royo. CEO
- **Phone:** 34 916591670 • [genzymespain@genzyme.com](mailto:genzymespain@genzyme.com) • <http://www.genzyme.com>

• **Short description:** The discovery and development of innovating products and services for serious pathologies, with special attention to rare diseases. \*Genzyme S.L. is a subsidiary of Genzyme Corporation through Genzyme BV in Naarden (The Netherlands), dedicated to the development and introduction of therapeutic solutions for unresolved medical problems.

• **Products:** Lysosomal Storage Diseases: Gaucher, Fabry, Hurler and Pompe diseases. Hyperphosphatemia in chronic renal disease. Oncohematology. Articular Viscosupplementation. Prevention of surgical adhesions. Biomaterials. Immunological disorders. Neurodegenerative diseases. Cellular therapies.

• **Interest areas:** Rare diseases/Orphan drugs. Renal disease. Oncology / Transplant.



### GH GENHELIX S.A.

- **Contact:** David Marcos del Blanco. Director of Corporate Strategy
- **Phone:** 34 987219558 • [dmb@genhelix.com](mailto:dmb@genhelix.com) • <http://www.genhelix.com>

• **Description:** Genhelix applies the highest standards of quality and the most advanced technology in protein production.

Our main asset, nonetheless, is our top-class staff which has a long tradition in top-class companies such as Lonza, Genentech, GSK etc. Our main services include:

Process Development; Preclinical, Clinical and Commercial Manufacturing under contract (Monoclonal Antibodies) and other biologics as well as biosimilars.

Scale-up, engineering and validation batches.

cGMP manufacturing fully documented (20, 50, 200, 600 and 3 x 2000 l FULLY DISPOSABLE).

Dossiers for main regulatory authorities (FDA, EMA, MHLW of Japan etc.).

Our partnering initiatives are focused on establishing collaborative relationships in the fields of: a) Monoclonal Antibodies and other recombinant proteins from Preclinical to Commercial scale. b) biosimilars (follow-on biologics) to reinforce our current projects in this area.



### Gilead Sciences, S.L.

- **Contact:** Roberto Urbez Plasencia. General Manager
- **Phone:** 34 913789830
- [roberto.urbez@gilead.com](mailto:roberto.urbez@gilead.com) • <http://www.gilead.com>

• **Short description:** Investigate, Develop and commercialize innovative drugs in therapeutics areas with uncover needs, with the objective to improve curation and surveillance rates in patients with severe infectious diseases.

• **Products:** HIV: VIREAD(Tenofovir disoproxil). EMTRIVA (Emtricitabina). TRUVADA(Tenofovir disoproxil y emtricitabina en un solo comprimido). ATRIPLA (Tenofovir disoproxil, emtricitabina & efavirenz, one pill, once a day) HEPATITIS B: HEPSERA (Adefovir dipivoxil), VIREAD (Tenofovir disoproxil) ANTIFUNGAL: AMBISOME(Anfotericina B liposomal).



### GP-PHARM, S.A.

- **Contact:** Isabel Bazán. Assistant CEO
- **Phone:** 34 936388000 • [ibazan@gp-pharm.com](mailto:ibazan@gp-pharm.com) • <http://www.gp-pharm.com>
- **Short description:** Research, development, manufacture and commercialization of Injectable products for the areas of Oncology, Nervous Central System, Cardiology and Urology. Based on two Drug Delivery Technological Platforms (Micro- nanspheres and Liposomes)

- **Products:** Development and Contract Manufacturing services based on the two Drug Delivery Platforms of injectable drugs (Micro- Nanspheres and Liposomes). Products in phase of commercialization or register (Oxetotide-Irinotecan-Leuprolide-Oxaliplatin-Gemcitabine). RD Projects in different phases of development (Oncology-CNS-Cardiovascular)
- **Interest areas:** Utilization of our Delivery Systems for development new molecules or for improvement of current molecules that already have lost patent. Alliances with pharmaceutical companies to take our products to the Market (USA, Japan, China, India). Alliances with pharmaceutical companies to do joint development of GP-Pharm's projects. Manufacture and Development for pharmaceutical companies in our Laboratories and Manufacturing Plant.



### Grifols Engineering S.A.

- **Contact:** Oriol Argemi. Business Development Manager
- **Phone:** 34 935710042

- [oriol.argemi@grifols.com](mailto:oriol.argemi@grifols.com) • <http://www.grifolsengineering.com>
- **Description:** Grifols Engineering is a company specialized in biotech and sterile manufacturing processes. Grifols Engineering offers consultancy and engineering services and also machinery development for the biotech industry (Ultrafiltration units, Filtration Skids, fermentors, CIP's, etc...) We have the know-how to design projects and specific machinery which comply with the European health authorities and the US FDA
- **Interest areas:** Biotechnology. Technological applications for medical purposes.



### Grupo Farmasierra

- **Contact:** Tomás Olleros. President
- **Phone:** 34 916 570 659
- [tomas@farmasierra.com](mailto:tomas@farmasierra.com) • <http://www.farmasierra.com>

- **Short description:** Pharmaceutical group of companies specialised in Research & Development, Manufacturing, Distribution and Marketing of Medicines, Food Supplements and Cosmetics operating at national and international level
- **Products:** Gynaecology: Remifemin, Carbocal 600 mg, Carbocal D, Carbocal D Masticable, Tricolam, Flucosil gel. Paediatrics: Calcio 20 emulsión, Calcio 20 complex, Calcio 20 Fuerte, Aminoveinte, Trofalgón, Trilombrin. Urology: Prosturo. Generics: Acetilcisteína, Pain & Inflammation: Ibuprofeno Farmasierra 5% gel, Ibuprofeno Farmasierra 50 mg/g gel mentolado, Astefor, Ibustick. Central Nervous System: Si-nequan. Antiinfectives: Terramicina, Terra-Cortril. Línea 20: Ferro 20, Multivitamínico Farmasierra. Food Supplements: Bifibran, Lactospor, Omega 3, Visdon, Nutrobal, Aceite de Onagra Cosmetics.
- **Interest areas:** In terms of services GRUPO FARMASIERRA offers: Technological Development and High Tech Contract Manufacturing Services. Research & Development. Manufacturing of investigational Medicinal Products (IMP). Licences out. Licences in Warehousing and Distribution Contract Services.



### Grupo P-Value

- **Contact:** Francisco Javier Navarro. General Director
- **Phone:** 34 902012292
- [javiernavarro@grupop-value.com](mailto:javiernavarro@grupop-value.com) • <http://www.grupop-value.com>

- **Short description:** Support biotechnology companies with their research and development programs, involved in the starting up and development of clinical research investigations through our technical and human means.
- **Services:** We are a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, due to our wide experience in Clinical Research. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies, depending on the needs of our clients.
- **Interest areas:** We are interested on collaborating on research and development projects with innovative medicines, or any other clinical research for all therapeutic areas.



### Histocell, S.L.

- **Contact:** Julio Font. CEO
- **Phone:** 34 946567900 • info@histocell.com • <http://www.histocell.com>
- **Short description:** Histocell Works in Tissue Engineering and Cell Therapy to develop innovative products for regenerative medicine.

Histocell facilities include a 65m2 certified clean room for GMP production of Cell Therapy medicaments, and several laboratories for quality control and R&D. Histocell works with differentiated adult stem cells obtained from adipose tissue.

- **Services:** Cell Therapy medicaments.

Divided in three main lines: GMP production of adult mesenchymal stem cells from adipose tissue and chondrocytes. Development of new Cell Therapy medicaments. Development of biomaterials for regenerative medicine

- **Interest areas:** Open new research lines to provide solutions to lacks in regenerative medicine and cell therapy, in addition to providing products that facilitate testing tasks in the pharmaceutical and cosmetic sectors. Its interest is directed to research groups with expertise in the field of new biomaterials.



### Iden Biotechnology S.L.

- **Contact:** Nora Alonso. CEO
- **Phone:** 34 948152122
- nora.alonso@idenbiotechnology.com • <http://www.idenbiotechnology.com>

- **Short description:** Iden Biotechnology is a company with scientific profile whose main activity is the generation, development and exploitation of biotechnological knowledge. Iden Biotechnology is a technology transfer company matching market demands with biotechnology research interests from universities and technology centers.

- **Products:** Iden Biotechnology develops biotechnological patents as its main product. The company also offers additional services as sub-contracted research projects, technical and financial project management, several biochemical analysis and Technology-Based Innovative Enterprises (EIBTs) creation advising.

- **Interest areas:** Present and future areas of interest for Iden Biotechnology include the development of new raw materials suitable for biofuels industry, biomaterials industry, as well as molecules with industrial, pharmaceutical, agricultural and nutritional value.



### Igen Biotech, S.L.

- **Contact:** David Segarra de la Peña. Managing Director
- **Phone:** 34 915102999
- igen@igenbiotech.com • <http://www.igenbiotech.com>

- **Short description:** IGEN Biotech is a privately owned company focused on R&D in the biomedical field. Its aim is to put into practice biomedical research and development and bring it to the market as products and services.

Its main field is development of new diagnostic methods, drugs and other therapeutic methods, focusing on the use of genomic, proteomic and cell therapy.

Genomic DNA extraction kit for low cell concentration samples.

Aptamers search and selection by SELEX Method.

Specific R&D services in molecular biology, cell biology, experimental surgery and medicine and proteomics areas.

Development of a growth factor for Parkinson's treatment.

Drug-screening based on aptamers for ischemic stroke treatment and diagnostics.

- **Interest areas:** Companies interested in aptamers development and application. Public R&D Centres, Foundations, Universities and research groups interested in technology transfer and implementation. CMO's and CRO's with experience in clinical trials. European partners related with aptamers development.



### ImmunNovative Developments

- **Contact:** Josep Lluís Falcó. CEO
- **Phone:** 34 934031945
- jlfalco@immunnovative.com • <http://www.immunnovative.com>

- **Short description:** Technological platform based in the development of new biological for the treatment, diagnosis and prevention of immune-based inflammatory disorders. ImmunNovative-01: treatment of bacterial sepsis. ImmunNovative-02: treatment of fungal sepsis

- **Interest areas:** Biotechnology. Sepsis. Proteins. GMP Development. Regulatory.



### Immunostep, S. L

- **Contact:** D. Ricardo Jara Acevedo. CEO
- **Phone:** 34 923294827 • [rjara@immunostep.com](mailto:rjara@immunostep.com) • <http://www.immunostep.com>
- **Short description:** IMMUNOSTEP is a Biotech company focused in the proteomic

area that research, develop, produce and market reagents and technologies both for research and diagnostics based on techniques such as Flow Cytometry, Proteomic Arrays or Multiplex Technology.

Our product areas include human and mouse cell immunophenotyping, human recombinant proteins, apoptosis, cytokines and growth factors, cell-cycle analysis, detection and quantification proteins.

• **Interest areas:** IMMUNOSTEP has its own research and diagnostics product development, production and quality control capabilities both for research and diagnosis products (EN ISO 13485:2003/AC:2007, Health License to Manufacture IVD)

We have a multidisciplinary program, which includes the production of antibodies, recombinant proteins and different protein array formats for the development of technologies, solutions and diagnostic kits in vitro.

At present we have in our pipeline, developments related to hematological malignancies, respiratory and other illnesses.



### Ingredientis Biotech S.L.U.

- **Contact:** Jesús Jiménez López. CEO
- **Phone:** 34 958750985 / 628735741 • [jesusjimenez@ingredientisbiotech.es](mailto:jesusjimenez@ingredientisbiotech.es)
- <http://www.ingredientisbiotech.es>
- **Short description:** Ingredientis Biotech is a biotechnology company dedicated to the discovery and de-

velopment of bioactive ingredients with effects on obesity, cardiovascular disease and diabetes, for functional food industries and dietetics.

• **Products:** Discovery of Active Ingredients Product Development Nutrition and Health Use of Byproduct

• **Interest areas:** Discovery of bioactive compounds. Nutritional evaluation of bioactive compounds and functional foods. Developing products, processes and technology to food. Membrane separation technologies, microencapsulation, solubilization and controlled release of nutrients and bioactive compounds.



### Inmunología y Genética Aplicada, S.A. INGENASA

- **Contact:** Carmen Vela Olmo. General Manager
- **Phone:** 34 913680501 • [cvela@ingenasa.es](mailto:cvela@ingenasa.es) • <http://www.ingenasa.es>
- **Short description:** Research, development, production and commercialisation of biotech products for animal health care.
- **Products:** Serologic diagnosis assays. Molecular diagnosis assays. Second generation vaccines.

• **Services:** Protein expression, monoclonal antibodies.



### Institut Univ. de Ciència i Tecnologia, S.A. (IUCT)

- **Contact:** Angeles Molina. Manager of the Business Projects Dept.
- **Phone:** 34 935793432 • [iuct.sales@iuct.com](mailto:iuct.sales@iuct.com) • <http://www.iuct.com>
- **Short description:** The mission of IUCT is to make use of its knowledge, expertise and capabilities to generate new technologies, products and processes for its industrial application in the Chemical, Pharmaceutical, Biotechnological and Environmental fields.

• **Products:** IUCT has a large pipeline of products, processes and technologies available due to the development of its own R&D programmes to be transferred to the industry in the following areas: Drug Discovery. Industrial Biotechnology. Drug Development. Green Chemistry. The development of this research projects led to IUCT to the creation of its own Technology Platforms available for its use in industrial projects. These IUCT Technology Platforms are: Industrial Biotechnology, Sustainable Chemistry, Drug Discovery, High Throughput Analysis, Optimization of the Chemical Processes and Drug Development.

• **Services:** Research, Development and Innovation projects under contract (Contract Research). IUCT has the capabilities to carry out contract research services taking into account viability and economic factors providing high-tech solutions at highly competitive prices. Technological services (Analysis and Consultancy): Services of analysis in different scientific areas making use of any of their laboratories of synthesis, physic-chemical, and microbiology analysis and its GMP complacence pharmaceutical pilot plant. Transfer of knowledge and specialised training: Open and customised training in broad areas of scientific knowledge. Organization of seminars, workshops and congresses.

• **Interest areas:** Pharmaceutical, biopharmaceutical and cosmetic sector  
Chemical industry and fine chemical. Food industry. Environmental/ Health at work.



### Instituto Biomar, S.A.

- **Contact:** Dr. Antonio Fernández. General Manager
- **Phone:** 34 987849200 / 913860159

- [ibiomar@institutobiomar.com](mailto:ibiomar@institutobiomar.com) • <http://www.institutobiomar.com>
- **Short description:** Discovery and development of new compounds and process of industrial interest from marine microorganisms
- **Products:** Research and development projects for companies in different industrial sectors. Production and selling of compound from microorganisms (GMP, APIs). Service of Analysis and structure determination of compounds. Service of Microbial Taxonomy. Provider of Cellular Lines, loaded in 96 well plates, for assays.
- **Interest areas:** PHARMACEUTICALS: discovery and development of new drugs (Cancer and antimicrobials in-house and other areas with different Partners). FOOD: natural preservatives. AQUACULTURE: microbiological control of infections. AGRICULTURE: microbial biopesticides. ENOLOGY: starters for alcoholic and malolactic fermentations. COSMETIC: antifungi, antioxidants and whiteners. BIOFUEL: production from cyanobacteria and microalgae.



### Instituto de Medicina Genómica (IMEGEN)

- **Contact:** Ana Martínez Hortigüela
- **Phone:** 34 963212340 • [anam.hortiguela@imegen.es](mailto:anam.hortiguela@imegen.es) • <http://www.imegen.es>
- **Short description:** Development of diagnostic tests based on genetic and genomic analysis,

focused on the detection of hereditary disorders. Design and production of sets of analysis based on molecular biology techniques, for the diagnosis of human diseases. Promotion of alliances and collaborations public- private.

- **Services:** Services of molecular diagnostic. Sets of molecular analysis of human pathologies. Research Projects in genomic.
- **Interest areas:** Diseases of hereditary transmission. Oncology. Farmacogenomics. Next generation sequencing.



### Integromics, S.L.

- **Contact:** Jose Maria Carazo, PhD. Principal Founder
- **Phone:** 34 958750627

- [carazo@integromics.com](mailto:carazo@integromics.com) • <http://www.integromics.com>
- **Short description:** To provide the market with up to date knowledge on IT solutions in the field of life sciences and particularly in genomics and proteomics.
- **Services:** The development and marketing of software for genomic and proteomic data management, analysis and mining. Professional services relating to these products.
- **Interest areas:** The development and commercialisation of software for genomics, proteomics and related sectors.



### Intelligent Pharma S.L.

- **Contact:** Anna Serra. Asistente de Dirección

- **Phone:** 34 934034551 • [aserra@intelligentpharma.com](mailto:aserra@intelligentpharma.com) • <http://www.intelligentpharma.com>
- **Short description:** Intelligent Pharma is a unique and innovative computational solution provider focused on drug design and target validation. Intelligent Pharma develops customized and highly-specialized computational solutions for our clients in order to reduce their costs, time and/or risks in their molecular research projects.
- **Products:** In early research stages we offer the following areas of expertise:  
Computer-aided drug design.  
Molecular modeling.  
Virtual screening.  
Compound library management and intelligent accessory tools.  
ADME/Tox modeling.  
Knowledge extraction and data mining from chemical and biologic databases.  
Biologic image processing.  
Improved/enhanced supercomputational research infrastructure.
- **Interest areas:** Drug discovery.



## Inversiones financieras Perseo

- [perseo@iberdrola.es](mailto:perseo@iberdrola.es)
- <http://www.iberdrola.es/webibd/corporativa/iberdrola?IDPAG=ESWEBRESINNINI>

• **Short description:** Perseo is an IBERDROLA development capital initiative dedicated to investment in innovative technology for renewable power generation and reducing the environmental impact of existing power generation systems. To this end, Perseo has an annual budget of  $\approx 6$  million, which is

used to guarantee IBERDROLA's participation in the technologies of the future.

• **Long description:** PERSEO is an initiative that uses IBERDROLA development capital to invest in innovative renewable electrical energy generation technologies and technologies that reduce the environmental impact of existing generation systems. With this initiatives, IBERDROLA fosters the development of an innovative business network in new renewable generation technologies. PERSEO has an initial annual budget of 6 million euros to ensure the presence of IBERDROLA in the technologies of the future. The main technological lines in PERSEO's investment portfolio are:

- Marine energy.
- Solar energy (both photovoltaic and thermoelectric).
- CO<sub>2</sub> capture through the production of biofuels.
- Other technologies aimed at the production and distribution of clean electrical energy.
- Through PERSEO, IBERDROLA looks for projects that match the general features described above and that represent a new development in this technology.



## Janus Developments

- **Contact:** Natàlia Ferrer. Head of administration
- **Phone:** 34 934031351
- [nferrer@janusdevelopments.com](mailto:nferrer@janusdevelopments.com) • <http://www.janusdevelopments.com>

• **Short description:** JANUS DEVELOPMENT SL is a company specializing in the management of transitional stages of biomedical projects with a mission to transform knowledge into economic value and biomedical social.

JANUS has acquired licensing patent rights over 11 technologies for their early stage development and has worked with various hospitals, public research centers, foundations and private companies to define development plans for their technologies.

• **Interest areas:** JANUS, as areas of interest are all those companies, universities, hospitals ... with the need of our services, either to develop some technology to provide a counseling service.



## Labgenetics, S.L.

- **Contact:** Jorge Puente Prieto. General Manager
- **Phone:** 34 91 659 22 98
- [jorge.puente@labgenetics.com.es](mailto:jorge.puente@labgenetics.com.es) • <http://www.labgenetics.com.es>

• **Short description:** To carry out highly accurate and decisive genetic tests within a minimum response period. To apply the most advanced techniques to identify alterations in the DNA sequence related to the onset of the most prevalent hereditary diseases in Europe. To consolidate as the Reference Centre in Forensic Genetics and Human Genetic Identification Tests.

• **Products:** Forensic Genetics: Paternity testing, parentage (kinship) analysis and genetic identification (DNA fingerprinting) from any biological traces. Reference Centre in complex kinship testing and complex Forensic sample analysis. Detection of biological fluids (semen, blood and saliva) Clinical Genetics: Molecular Diagnostics of more than 250 hereditary diseases. Personalized Genetic Diagnostic Service (A la carte Diagnostic) to comprise rare diseases. Prenatal Genetic Diagnostic, including the fast aneuploidy screening by QF-PCR, and Preimplantational Genetic Diagnostic (PGD) to select genetically healthy embryos. Technology Transfer: Set up and start up of Molecular Biology turn-key laboratories, focused on human genetic analysis. The designed projects are highly flexible and are adjusted to the petitioner requirements. Scientific Advisory Services: Interpretation of expert reports based on DNA evidences in civil legal and penal procedures. Assistance to legal procedures as judicial experts to ratify specialist's reports based on DNA evidences. Theoretical and practical training in Forensic Genetics and Genetic Diagnostic techniques to professionals, private individuals, companies, laboratories and research teams.

• **Interest areas:** Development of new Molecular Diagnostic techniques. Projects of Forensic Genetics and Genetic Diagnostic training. Development and distribution of new Molecular Diagnostic Kits.



### Laboratorios Alpha San Ignacio Pharma S.L. (AlphaSIP)

- **Contact:** Miguel Roncales. DIRECTOR
- **Phone:** 34 976 512 887 • mroncales@alphasip • <http://www.alphasip.es/>
- **Short description:** AlphaSIP's main goal is to develop benchmark medical diagnostic devices to contribute to the improvement of the international healthcare system and foster advances towards personalized medicine

AlphaSIP is mainly focused in the Haematology sector to provide a medical diagnosis tools capable of detecting thrombosis risk.



### Laboratorios LETI, S.L. Unipersonal

- **Contact:** Ellen Caldwell. BU Director, Immunology and Vaccines for Global Health
- **Phone:** 34 933945350 • ecaldwell@leti.com • <http://www.leti.com>
- **Short description:** The company's objective is to contribute to sustainable improvements in health and well-being, paying special attention to prevention, early diagnosis and treatment of personal healthcare. Having innovative, patented products is a key objective of LETI. The company dedicates to research and development between 8 and 10% of its turnover. The company is focused in four areas—allergy, dermatology, diagnostics, and vaccines. The Allergy Unit specialises in the production of allergenic extracts for in vivo diagnosis and etiological treatment of allergies. The Dermatology and Personal Healthcare Unit (DPH) is focused on the manufacturing of skincare and other, personal healthcare products. The Diagnostics Unit specialises in in vitro diagnosis and culture media for assisted reproduction. The Vaccine Unit is focused on the development of vaccines for the prevention of leishmaniasis.

and well-being, paying special attention to prevention, early diagnosis and treatment of personal healthcare. Having innovative, patented products is a key objective of LETI. The company dedicates to research and development between 8 and 10% of its turnover. The company is focused in four areas—allergy, dermatology, diagnostics, and vaccines. The Allergy Unit specialises in the production of allergenic extracts for in vivo diagnosis and etiological treatment of allergies. The Dermatology and Personal Healthcare Unit (DPH) is focused on the manufacturing of skincare and other, personal healthcare products. The Diagnostics Unit specialises in in vitro diagnosis and culture media for assisted reproduction. The Vaccine Unit is focused on the development of vaccines for the prevention of leishmaniasis.

• **Interest areas:** Laboratorios LETI is interested in research and development collaboration in the areas of diagnostics, vaccines, and therapies related to allergy, dermatology, immunology and leishmaniasis. In addition to research and development, the company is interested in expanding access of our products to international markets.



### Laboratorios Ojer Pharma

- **Contact:** Carlos González Ojer. Managing Director
- **Phone:** 34 948287859
- cgonzalez@ojerpharma.com • <http://www.ojerpharma.com>

• **Short description:** Ojer Pharma is a spin-off company of the University of Navarra that aims at developing a pipeline of innovative dermatological medicines with a national and international scope. Due to its tight collaboration with prestigious research centres from the public sector (Service of Development of Medicines, SDM, of the University of Barcelona) and the private sector (Center for Applied Pharmacobiology Research, CIFA, and the University Hospital of the University of Navarra, CUN), the company has direct access to cutting edge findings in medicine development, which allows us to provide our clients with more effective dermatological solutions. Ojer Pharma Laboratory is the centre of a whole collaboration system in which it leads the major part of the research and development process. Our Laboratory seeks for partners interested in co-developing dermatological drugs and willing to in-license its products. Ojer Pharma's products portfolio consists of a wide set of innovative dermatological medicines for common dermatological diseases. The aim of our medicines is the simultaneous treatment of aetiological and symptomatological aspects of skin conditions, contributing to reduce both illness permanence and consumption of multiple products. The company is specialized in skin infections, dermatitis and pressure ulcers.



### Laboratoris Sanifit, S.L.

- **Contact:** Bernat Isern Amengual. Scientific Director
- **Phone:** 34 871 70 30 62
- laboratoris@sanifit.com • <http://www.sanifit.com>
- **Short description:** Laboratoris Sanifit is a biotechnology company dedicated to the research and development of health products and to transferring this research for the benefit of society. Sanifit's work focuses on research and development of innovative drugs and products for the treatment and/or prevention of diseases, mainly in the cardiovascular, renal, osteoporosis and dental fields.

• **Products:** SNF-471: experimental drug in preclinical phase indicated for the treatment of cardiovascular calcifications. SNF-472: experimental drug in preclinical phase indicated for the treatment of coronary calcification in end stage renal disease patients. SNF-571: experimental drug in preclinical phase for the treatment of calcic renal lithiasis. SNF-671: experimental drug in preclinical phase for the treatment of osteoporosis. ASB-01: consumer health products for the treatment of dental calculi. Patents granted.

• **Interest areas:** Drugs and other products in the following areas: Urology. Cardiology. Dermatology. R+D of new drugs.



### Laimat Soluciones Científico Técnicas, S.L.

- **Contact:** Josefina Pedrajas. Director
- **Phone:** 34 958750951 / 858100141
- fpedrajas@laimat.com • <http://www.laimat.com>
- **Short description:** Reach: Applied investigation for the development of new products for the biotechnological, agro food, pharmaceutical and chemical industries.

cal, agro food, pharmaceutical and chemical industries.

Mission: Contribute to improve society's health and welfare, participating in the development of new products for pharmaceutical and agro food industries, by applied investigation using physic-chemical particles properties Knowledge.

R&D: Microencapsulation of active ingredients for new materials, intelligent textiles and food. Development of electrochemical sensors with applications in food security, toxicology and diseases diagnosis. Services as external R&D department for companies from the agro food, pharmaceutical and chemical sectors. Provides solutions to physicochemical problems: Solubility, Stability, Formulation, Microencapsulation.

• **Interest areas:** R&D Projects, in Health, Nanotechnology and Biotechnology areas: Microencapsulation and controlled delivery of drugs. Adaptation of a new analytical technology for determination of toxics and early diagnosis. Provides: portability, quickness, sensitiveness, selectivity and easy use. By-products reevaluation. Polymorphs determination. Physicochemical characterization of biopolymers. Solubility. Stability control.



### Lipopharma Therapeutics

- **Contact:** Vicenç Tur. CEO
- **Phone:** 34 971439886

• v.tur@lipopharma.com • <http://www.lipopharma.com>

• **Short description:** Lipopharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and initial clinical development of a new generation of medicines associated with a novel therapeutic approach: Membrane Lipid Therapy (MLT).

• **Products:** Minerval®, a Ras/MAP Kinase pathway inhibitor, is showing very high efficacy with no toxicity in several types of cancer, clearly outperforming approved drugs. A promising MLT based pipeline is also being consolidated, with potential applications in CNS (Alzheimer's Disease), cancer, inflammation or Spinal Cord Injury.

• **Interest areas:** Lipopharma is seeking new partnerships and collaborations with pharmaceutical companies in order to complete the clinical development for Minerval® in cancer. We are also interested in R&D collaboration agreements to further advance our new MLT based products in attractive areas such as AD, inflammation, cardiovascular diseases or Spinal Cord Injury.



### Lonza Biologics Porriño, S.L.

- **Contact:** Luis Sánchez Ureña. Production Director

• **Phone:** 34 986344060

• lonzaporrino@lonza.com • <http://www.lonza.com>

• **Short description:** Produce recombinant monoclonal antibodies from mammalian cell culture.

• **Products:** Cell culture and recombinant monoclonal antibodies



### Master Diagnostica, S.L.

- **Contact:** Juan Jiménez Rodríguez. Manager
- **Phone:** 34 958271449

• [juan.jimenez@vitroweb.com](mailto:juan.jimenez@vitroweb.com) • <http://www.masterdiagnostica.com>

• **Short description:** Design, development and commercialization of systems for molecular and immunohistochemical diagnostic in oncology and infectious diseases.

• **Products:** Antibodies and detection systems for immunohistochemistry. Kits for molecular analysis of gene rearrangements in lymphomas. Kits for screening and genotyping of human papillomavirus by PCR. Kits for molecular diagnostic of zoonotic bacteria Kits for mutational analysis of tumoral genes.

• **Interest areas:** Molecular diagnostic in infectious pathology. Mutational analysis of genes involved in pharmacogenetic and inherited cancer.



## Merck S.L.

- **Contact:** Marta Gállego. Dpto. Comunicación
- **Phone:** 34 917454400 • [comunicacion@merck.es](mailto:comunicacion@merck.es) • <http://www.merck.es>
- **Short description:** Merck is the pharmaceutical and chemical company with more tradition in the world, with origins in 1668. Merck seeks business success with a formula based on values and generate economic value.

Our strategy is supported on three concepts that define Merck's strategy: Sustain, Change and Grow.

Merck is concentrated in two business segments: pharmaceuticals and chemicals. All activity of the company is organized into four Divisions: Merck Serono and Merck Consumer Health Care (pharmaceutical) and Performance Materials and Merck Millipore (chemical).

• **Interest areas:** The Merck Serono division aims to provide innovative solutions to patients. We are specialized in the treatment of cancer, neurological diseases, infertility, hormonal and metabolic disorders, cardiovascular disease and other diseases with significant unmet medical needs, such as phenylketonuria. And we continue investigating to provide patients with therapeutic advances in our actual business.



## Merck, Sharp & Dohme de España, S.A. (MSD)

- **Contact:** Carmen López-Lavid. Communication Director
- **Phone:** 34 913210600
- [carmen\\_lopez\\_lavid@merck.com](mailto:carmen_lopez_lavid@merck.com) • <http://www.msd.es>

• **Short description:** Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them. MSD

• **Products:** MSD pipeline has over 20 promising late-stage candidates spanning the stages of life, and we have a presence in more than 100 countries around the world, including emerging markets. MSD also publishes unbiased health information as a non-profit service. To visit MSD pipeline: <http://www.merck.com/research/pipeline/home.html?WT.svl=content>

• **Interest areas:** Scientific discovery and development have always been the cornerstones of our company. Today, we conduct research in a broad range of therapeutic categories including cardiovascular disease, infectious diseases, vaccines, cancer, neurology and women's health. And, to help achieve our goal of saving and improving lives around the world, we are expanding our capabilities in new areas, such as biologics.



## Miltenyi Biotec

- **Contact:** Iván Alvarez-Sierra. Country Manager
- **Phone:** 34 915121290
- [macs@miltenyibiotec.es](mailto:macs@miltenyibiotec.es) • <http://www.miltenyibiotec.com>
- **Short description:** Miltenyi Biotec develops, produces, and markets state-of-the-art products and services for cell separation, cell analysis, cell culture, molecular biology, and clinical research applications.

• **Products:** MACS® Technology for Cell Separation. AutoMACS® CliniMACS®. Microarrays & Bioinformatics. Adsorbers for Therapeutic Apheresis.



## Monsanto Agricultura España, S.L.

- **Contact:** Jaime Costa
- **Phone:** 34 913 432 701
- [jaime.costa@monsanto.com](mailto:jaime.costa@monsanto.com) • <http://www.monsanto.es>

• **Short description:** To attend the world's food needs.

To conserve natural resources.

To protect the environment.

To serve our customers and our shareholders.

• **Products:** Monsanto is a group of companies whose activity is aimed at the development and improvement of agriculture and the food sector. Over the last 30 years Monsanto has been focusing in research, development and commercialization activities for agriculture and it has concentrated its aims on providing sustainable agricultural systems, beneficial for farmers all over the world. Monsanto is committed to developing safe technologies and products that are beneficial for both farmers and consumers. Our most outstanding products are our herbicides from the Roundup range and the Dekalb brand seeds. For further information on our products go to: <http://monsanto.es/monsantoes/productos.html>

• **Interest areas:** Plant Biotechnology. Conservation agriculture. Biofuels.



### Neocodex, S.L.

- **Contact:** Evaristo Fernández. Administration Manager
- **Phone:** 34 955047618 • efernandez@neocodex.esm • <http://www.neocodex.com>

- **Short description:** NeoCodex's objective is to generate value by discovering and developing preproducts to feed standard production processes for new pharmaceuticals. The company discovers and develops these pre-products up to pre-clinical stage. DNA biorepository. DNA genotyping and genomic support services. Detailed interpretation of results derived from whole genome scans. Integral research services in genomics. Molecular diagnostic. Patents derived from our research activity
- **Interest areas:** Neocodex, using genomic approaches, has discovered several drug targets involved in the development of diseases such as Alzheimer's disease, Parkinson's disease, cardiovascular risk and cancer. We are very interested in carrying out proofs of concept on those discoveries in animal models and to perform clinical trials.



### Neuron Bio

- **Contact:** Javier Velasco. CEO
- **Phone:** 34 958 750 598 • [info@neuronbio.com](mailto:info@neuronbio.com) • <http://www.neuronbio.com>

- **Short description:** Neuron Bio specializes in the development of biosolutions for the pharmaceutical, chemical, energy and agro-food industries via its divisions: BioPharma, BioIndustrial, Bioservices and Innofood by Neuron. The Neuron BioPharma research division is devoted to the discovery and assessment of pharmaceuticals and nutraceuticals to treat and combat neurodegenerative illnesses such as Alzheimer's disease. The bioindustrial division, Neuron BioIndustrial, is devoted to the development of bioprocesses intended for application in the pharmaceutical, chemical and the biofuels sector. Neuron Bioservices division offers in vitro and in vivo assays for the discovery and evaluation of drug candidates. Innofood by Neuron offers a versatile team with wide experience in the development of complete R&D+i projects for the agro-food industry.



### Neuroscience Technologies, S.L.

- **Contact:** Dra. Cristina Quiles. Director
- **Phone:** 34 93 402 01 64 • [cquiles@nsc-tec.com](mailto:cquiles@nsc-tec.com) • <http://www.nsc-tec.com>
- **Short description:** Research on the mechanisms of neuropathic pain. Development of new therapeutic drugs.

- **Products:** New drugs for neuropathic pain treatment
- **Services:** Studies on patients with neuropathic pain. Studies on experimental models of axonal hyperexcitability.
- **Interest areas:** Development of new drugs targeting axonal hyperexcitability. Development of diagnostic devices for neuropathic pain.



### Newbiotechnic, S.A.

- **Contact:** Manuel Rey. General Manager
- **Phone:** 34 955 776 710
- [mrey@nbt.com](mailto:mrey@nbt.com) • <http://www.newbiotechnic.com>

- **Short description:** To identify, protect and commercialise microbiological and molecular tools with an immediate, practical application in the farming and agrifoodstuffs sector, which are safer for the consumer and more respectful with the environment. Founded in 1999, NBT is an R&D company in farming and agrifoodstuff biotechnology, with three business areas: 1) Biological control agents 2) Gene technology for improving crops and 3) Molecular diagnostics services. It has genomics and phytopathology laboratories and a pre-industrial production plant and a HR team, including six people with PhDs. With a technological portfolio of over 20 patents and a research network of 45 groups at world level, NBT is a pioneer in the development and registration of biofungicides and leader in molecular phytopathology.
- **Products:** Biological Control Agents (biofungicides, bioinsecticides). Tools for plant improvement by genetic transformation.
- **Services:** Genomic and Bio-IT services. Phytopathological diagnostics. Agrifoodstuff diagnostics. Veterinary diagnostics. Human genetic diagnostics.
- **Interest areas:** The development of microbiological products for crop protection. Submerged fermentation technology and product recuperation. Co-development/ distribution of natural products for agriculture (microbiological products, plant extracts, organic extracts, etc.). Development of diagnostic genetic tests for farming, aquaculture, veterinary and food product applications. The development of concept tests in plant genetic transformation.



### Noray Bioinformatics, S.L.U. (NORAYBIO)

- **Contact:** Marta Acilu. General Manager
- **Phone:** 34 944 036 998 • [info@noraybio.com](mailto:info@noraybio.com) • <http://www.noraybio.com>
- **Short description:** Supports the life science sector. Aims to meet the needs of work in all aspects of

the biosciences.

- Animal research centres.
- Biobanks.
- Centres for assisted reproduction.
- Laboratories and research units.

Pharmaceutical industry.

- **Products:** AniBio. NorayBanks. Fivisoft. NorayLIMS. NorayLab. Noraymet.
- **Interest areas:** NorayBio looks for strategic alliances and partnerships to continue the internationalization of its products and the company by opening branch offices abroad.




### Noray Biosciences Group (Noray BG)

- **Contact:** Julio Font. President
- **Phone:** 34 944036998 • [info@noraybg.com](mailto:info@noraybg.com) • <http://www.noraybg.com>
- **Short description:** Noray BG is a holding group focussed on Biosciences, whose mission is to manage and integrate the companies in the Biosciences sector to enhance their access to the market and their internationalization. NorayBio is currently composed by two companies: Histocell and NorayBio.

• **Services:** Noray BG is a holding dedicated to the management of its companies (NorayBio and Histocell, at the moment), in different fields like strategic management, business development, internationalization, financial management and human resources.

• **Interest areas:** Noray BG's strategy for the near future is based on the continuous growth by means of collaboration agreements with other companies and institutions, development of new innovative products and acquisition or merger with new firms, everything done with the firm idea of motivating the expansion throughout the European and international market.



### Noscira

- **Contact:** Belén Sopesén Veramendi. Managing Director
- **Phone:** 34 918061130 • [bsopesen@noscira.com](mailto:bsopesen@noscira.com) • <http://www.noscira.com>
- **Short description:** To research, develop and commercialise innovative drugs for the treatment and prevention of diseases of the Nervous System with unmet medical needs, especially Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP; rare disease).

• **Products:** Two compounds in clinical development: Nypta® (NP-12), only GSK-3 inhibitor in clinical phase II, for AD and PSP; NP-61, beta-amyloid modulator and acetylcholinesterase inhibitor, currently in clinical phase I. Projects in earlier stages: Neuroprotection (alpha-secretase activators); NP-103 (GSK-3 inhibitor of marine origin); Cell therapy project.

• **Interest areas:** Noscira is open to the negotiation of license Nypta® (NP-12) and NP-61 for the US and Japan, while maintaining certain rights in Europe. Noscira also contemplates the possibility of establishing specific collaboration agreements aimed at the co-development of any of its lines of research or compounds in the area of nervous system.



### Omnia Molecular, S.L.

- **Contact:** RG Klingmann. CEO • **Phone:** 34 934020158
- [rklingmann@omniamol.com](mailto:rklingmann@omniamol.com) • <http://www.omniamol.com>
- **Short description:** Omnia Molecular Ltd. (Omnia) leverages proprietary technology to rapidly design first-in-class antibiotics targeted at difficult-to-treat hospital infections. Lead compounds are optimized and

proven effective in animal models before being presented as candidates for co-development with pharma industry partners. • Omnia's platform applies a completely new approach to the selection and optimization of pharmacological compounds. Our proprietary platform is based on a validated molecular target of universal distribution and is currently being used to develop compounds against MRSA (Methicillin-resistant *Staphylococcus aureus*), a bacterium responsible for several difficult-to-treat infections in hospital. Our technology combines cellular assays that simultaneously evaluate compounds for several pharmacological parameters, thus accelerating and improving current methods for the discovery and development of anti-infective drugs. The resulting compounds are pharmacologically optimized and proven effective in a mouse model of infection.

• **Interest areas:** We are seeking a co-development partner for our lead program against MRSA. The partner should have the capacity to contribute the resources and expertise to move the selected drug candidate from IND through clinical trials.



### One Way Liver Genomics, S.L. (OWL GENOMICS)

- **Contact:** Julián Sánchez
- **Phone:** 34 944318540 • [jsanchez@owlgenomics.com](mailto:jsanchez@owlgenomics.com) • <http://www.owlgenomics.com>
- **Short description:** OWL Genomics is a biotechnology with the mission to contribute to the solution of

important problems in the field of human health that present serious deficiencies in diagnosis and treatment. The activity of the company is centered in the area of human health, with pioneering applications in the international scientific panorama, and whose objective is to identify, validate, patent and commercialize diagnostic and/or prognostic systems, as well as therapeutic targets involved in the development of complex diseases.

- **Products:** To consolidate the developments of OWL Genomics as a technology-based company, an innovative line of development has been developed, Metabolomics, which allows opening diagnostics to the massive identification of specific biomarkers for a given pathology. Currently there are two business lines: In vitro serum based Non Alcoholic Fatty Liver Disease diagnosis test. R & D services to pharmaceutical and biotechnology companies in key areas such as biomarkers discovery, clinical studies, diagnostics and toxicology.
- **Interest areas:** OWL Genomics is currently applying its know-how in metabolomic technology to other diseases with complex diagnostics such as Bladder Cancer and CNS Diseases, with a personalized medicine approach. The company is seeking for appropriate partners to establish commercial and strategic alliances for new products and markets.



### Operon, S.A.

- **Contact:** Tomás Toribio. General Manager
- **Phone:** 34 976 503 597 • [Info@operon.es](mailto:Info@operon.es) • <http://www.operon.es>

• **Short description:** To be international leader in 6 technologies relating to In Vitro Diagnosis: Monoclonal antibodies, recombinant antigens, agglutination latex, immunochromatography, ELISA and Molecular Biology tests.

• **Services:** Research, development and manufacturing of Monoclonal Antibodies Research, development and manufacturing of Recombinant Antigens RD&I and manufacturing of In Vitro Diagnostic kits based on immunological reactions RD&I and manufacturing of In Vitro Diagnostic kits based on molecular biology.

• **Interest areas:** Industrial production and purification of monoclonal antibodies and recombinant antigens Design and large scale production or with own brand of new In Vitro Diagnostic tests.



### Oryzon Genomics S.A.

- **Contact:** Carlos Buesa. CEO
- **Phone:** 34 935151313 • [cbuesa@oryzon.com](mailto:cbuesa@oryzon.com) • <http://www.oryzon.com>
- **Short description:** Oryzon is a biomarker discovery company with a Diagnostic and Therapeutic pipeline focused in Oncology and Neurological disorders. Oryzon's mission is the identification of gene functions and proteins so as to design and develop biotechnological products that improve people's health.

• **Services:** The company has an integrated bio-marker discovery and validation platform and develops its own core research program, with an increasing number of projects in selected niches of the biomedicine arena always in partnership with the Academia and Pharmaceutical companies.

• **Interest areas:** Oryzon has several important strategic alliances with food, biotech and pharmaceutical companies and is looking for industrial pharma and food partners to launch new global projects.



### Palau Pharma S.A.

- **Contact:** Heidi Sisniega. Chief Business Officer
- **Phone:** 34 93 863 04 83 • [hsisniega@palaupharma.com](mailto:hsisniega@palaupharma.com) • <http://www.palaupharma.com>

• **Description:** Palau is a product-driven biopharmaceutical company focused on the Discovery and development of revolutionary and differentiated new medicines that are designed to address the unmet medical needs of patients suffering from inflammatory and autoimmune diseases. Its business strategy consists of developing compounds up to the point of obtaining their proof-of-concept in humans, and then establishing strategic alliances with multinational pharmaceutical companies for their subsequent development and commercialization. Palau Pharma has a broad portfolio of projects at different stages of development from early discovery to the late clinical stages, and have forged partnerships with leading pharmaceutical companies such as GlaxoSmithKline, who is developing Palau Pharma's leading project, albaconazole, for nail fungal infections (onychomycoses). For more information about our projects and partnerships, visit our website [www.palaupharma.com](http://www.palaupharma.com). At Palau, partnering plays a strong role in both our business model and our development philosophy. We are actively: (i) Seeking innovative drug discovery alliances to jointly design and develop novel small molecule drugs based on targets and indications of common interest, (ii) Establishing partnerships with leading biotechnology and pharmaceutical companies for the late stage development and commercialization of our projects beyond Phase II clinical trials, (iii) Pursuing partnerships in order to broaden and diversify our development pipeline through the in-licensing of new chemical entities or new formulation projects.



### PANGAEA BIOTECH, S.L.

- **Contact:** Elizabeth Breedlove. Corporate Development
- **Phone:** 34 93 546 01 19 • [ebreedlove@pangaeabiotech.com](mailto:ebreedlove@pangaeabiotech.com) • [www.pangaeabiotech.com](http://www.pangaeabiotech.com)

• **Short description:** To become a top EU centre for cancer treatment, a worldwide reference for in-vitro diagnostics (IVD) of treatment response, and to develop innovative anti-cancer drugs with major clinical and commercial potential based on targeted approaches (i.e., early identification of the putative target population).

Discovery and development of gene signatures predictive of sensitivity to anticancer agents. Biomarker discovery agreements applicable to drugs under development. Service agreements to third parties. Technology transfer agreements.

• **Interest areas:** Business development and out-license of our predictive models to diagnostic companies. Strategic alliances with pharma and biotech companies in the field of cancer pharmacogenomics. Service agreements on pharmacogenomics. Development of new technologies applicable to cancer pharmacogenomics. Permalink.



### Parexel International

- **Contact:** Georgina Singleton. Director, Marketing
- **Phone:** 34 +44 1895614530
- [georgina.singleton@parexel.com](mailto:georgina.singleton@parexel.com) • <http://www.parexel.com>

• **Services:** PAREXEL is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.



### Pevesa, S.L.

- **Contact:** Iñaki Mielgo. General Manager and CEO
- **Phone:** 34 955946024 • [imielgo@pevesa.es](mailto:imielgo@pevesa.es) • <http://www.pevesa.es>

• **Short description:** To be a reference in the design, production and R&D in the area of proteins, peptics and amino-acids and biochemical compounds employing biotechnology as a work tool.

• **Products:** Proteins, peptics, biochemical products.

• **Services:** Industrial Biotechnology and Biochemical Engineering. Enzyme and Fermentation Technology. RD&I Laboratories and Pilot plant.

• **Interest areas:** Contract manufacturing, custom made manufacturing. Product development. Collaboration, research and development agreements for new products. Joint Ventures. Investment in biotech projects.



### Pharmamar, S.A.U.

- **Phone:** 34 918466000
- [pharmamar@pharmamar.com](mailto:pharmamar@pharmamar.com) • <http://www.pharmamar.com>
- **Short description:** PharmaMar, founded in 1986 and part of Grupo Zeltia, is a biopharmaceutical company which explores the seas to find innovative treatments. PharmaMar is conducting a pioneering marine biotechnology programme in search of new marine-based drugs. The company's research taps the sea, whose enormous biodiversity makes it a model for discovering new anti-tumour drugs.

• **Products:** Yondelis® has received Authorization for Commercialization from the European Commission for advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Yondelis® has also received marketing authorization from the European Commission in November 2009 for the treatment of platinum-sensitive relapsed ovarian cancer. Yondelis® is also undergoing Phase II trials on breast, prostate, lung and paediatric tumours. Yondelis® has actually received marketing authorization in 63 countries. Plitidepsin is undergoing Phase III trials for multiple myeloma and Phase II for T-cell lymphoma and myelofibrosis. PM00104 is undergoing phase II trials in endometrial and cervical cancer. Elisidepsin is undergoing phase II trials on no microcitic lung cancer. PM01183 has finished phase I trials on solid tumours.

• **Interest areas:** Our business strategy is to find co-development partners who are able to successfully contribute to a joint development. To this end, we seek partners who can contribute to successfully develop our product portfolio of marine origin in Europe, USA and Japan. PharmaMar retains commercialization rights for Europe while granting licenses for all territories outside of Europe.



## Pioneer Hi-Bred Spain, S.L.

- **Contact:** Alberto Ojembarrena. Operations Manager
- **Phone:** 34 954298300 • alberto.ojembarrena@pioneer.com • <http://www.pioneer.com>
- **Short description:** The development, production and commercialisation of agricultural seeds and inoculants for the conservation of animal fodder.
- **Products:** Maize, Sorghum, sunflower, cotton, soybean, corn, lucerne, rape seeds Lactic bacteria inoculants for

animal fodder conservation

- **Services:** Comprehensive agronomic services of complete advisory service to agricultural users of the plant species marketed.
- **Interest areas:** The development of varieties of plant species and inoculants for agriculture and stock farming. Development of methods and knowledge concerning stock feeding. Development of varieties of plant species for human nutritional use Development of varieties and processes for the bio-energy industry Development of processes for improving and knowing the agricultural crop environment better (soils, waters, efficiency and irrigation methods, abiotic factors, pest control, etc.).



## Probelte Biotecnología

- **Contact:** Pedro Martínez Ortiz. Managing Director
- **Phone:** 34 968307250
- pedromartinez@probelte.es • <http://www.probelte.es/>
- **Short description:** PROBELTE BIOTECNOLOGIA has been defined, right from the start, like an competitive and in-

novative company with the corporate purpose of researching, developing, innovating and commercialising natural bio-active principles, either, functional or technological, obtained through green technologies and, addressed to the food, cosmetic, pharmaceutical and veterinarian sectors.

- **Products:** Natural bio-actives principles like POMANOX and MEDITEANOX of high concentration and purity, obtained through physical procedures. Develop of applications of the bio-actives principles for uses like either functional or technological ingredients in the food, cosmetic, pharmaceutical and veterinarian industries. Obtaining of natural and systemic vaccines for using in aquaculture; developing of effective and efficient ways of administration.
- **Interest areas:** New developing of applications and uses of the bio-actives principles in the food and pharmaceutical sectors. Developing of new natural bio-actives principles through green technologies. Developing on new fish vaccines.



## ProRetina Therapeutics, S.L.

- **Contact:** Stuart Medina. General Manager

- **Phone:** 34 948317345
- stuart.medina@proretina.com • <http://www.proretina.es>
- **Short description:** Development of drugs for treatment of retinal diseases
- **Products:** PRO-001. Neuroprotective agent for treatment of retinitis pigmentosa. PRO-015. Gene therapy for treatment of retinitis pigmentosa
- **Interest areas:** Novel molecules with potential ophthalmological indications Sustained release technologies for intraocular delivery of therapeutic agents.



## Proteomika, S.L.

- **Contact:** Gorka Ramírez
- **Phone:** 34 944 064 525
- gramirez@proteomika.com • <http://www.proteomika.com>

• **Short description:** Kits development and production for in vitro diagnostic and treatment response evaluation. Protein biomarkers identification. Development and identification of new technologies for protein biomarker validation Design and development new technologies for biomarkers quantification.

Kits for in vitro diagnostic and therapeutic response monitoring for different cancers and autoimmune pathologies.

Methods for molecular typing in microbiology. Services of proteomic and citomic analysis.

- **Interest areas:** Looking for partnerships in the medical field in order to develop products focused on assays which detect and quantify protein and autoimmunity biomarkers. Development of monitoring systems to follow medical treatments with biological drugs. Those partners can be specialized in the development of new technologies and instrumentation to run internal products.



### Proteos Biotech, S.L.U

- **Contact:** Alina Girigan. Administration
- **Phone:** 34 915211588
- [info@proteosbiotech.com](mailto:info@proteosbiotech.com) • <http://www.proteosbiotech.com>

- **Short description:** Production and commercialization of recombinant enzymes for their application in cosmetics and pharmaceuticals.
- **Products:** Recombinant enzymes – Collagenase, Keratinase, Pz-Peptidase, Subtilisine
- **Services:** Bioprocesses and biocatalysis using recombinant enzymes.
- **Interest areas:** Cosmetics, Biopharmaceutical, Recombinant Enzymes Production.



### Proyecto de Biomedicina CIMA, S.L. (BITA)

- **Contact:** Antonio Martin. General Manager
- **Phone:** 34 948287561
- [amartin@proyectobiocima.com](mailto:amartin@proyectobiocima.com) • <http://www.proyectobiocima.com>
- **Short description:** Managing, patenting and exploiting all the results coming out from the research activity carried out in the CIMA project, a joint venture between a group of several first class spanish companies and the

CIMA (Research center for applied medicine owned by the University of Navarra

- **Products:** See the web [www.proyectobiocima.com](http://www.proyectobiocima.com)
- **Interest areas:** Licensing for the development of the results owned by the company, through licensing agreements with biotech companies or by setting up new companies to develop these results.



### Roche Applied Science

- **Contact:** Carlos Freixas. Director
- **Phone:** 34 935834000
- [carlos.freixas@roche.com](mailto:carlos.freixas@roche.com) • [www.roche-as.es](http://www.roche-as.es)

- **Short description:** "Roche Applied Science provides superior bioanalytical solutions for the life science market", the business areas offers integrated solutions for research applications, including all experimental steps that lead from sample to results.

- **Products:** With more than 2000 products for:

Genomics: Instruments and reagents for qPCR , nucleic acid extraction and analysis, pirosequencing and microarrays.

Proteomics reagents and cellular analysis.

Raw materials and industrial GMP Grade products, contract manufacturing and customized/ dedicated products.



### RPS Research Ibérica, S.L.U. (Grupo RPS)

- **Contact:** Esther Ramirez. Director General.
- **Phone:** 34 932158008
- [eramirez@rpsweb.com](mailto:eramirez@rpsweb.com) • <http://www.rpsweb.com>

- **Short description:** RPS, The Next Generation CRO, with offices in Europe, North America, Latin America, Asia and Africa, provides comprehensive global Phase I-IV clinical development solutions to the global Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries. RPS SPAIN has offices in Madrid and Barcelona. Early Development Support Services: Protocol Development, Study Design, Regulatory, Pharmacokinetic/Pharmacodynamic, Data-Management, Biostatistics, Integrated Report Writing, Multi-disciplinary consultation services... Full Service Clinical Development Phase I-IV: from study design through final clinical study report. Outsourcing Solutions in Clinical Development: R+D, Regulatory Affairs, Data-Management, Biostatistics, Pharmacovigilance, Monitoring, Quality Assurance.

- **Interest areas:** RPS provides scientific support and clinical expertise to participate in the Phase I-IV clinical development with Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries.



## Secugen, S.L.

- **Contact:** Begoña López Gimaré. Sole Officer
- **Phone:** 34 918063105 • b.lopez@secugen.es • <http://www.secugen.es>
- **Short description:** The company's main objective is the development of methodologies for DNA analysis applied to research and genetic diagnostics tests. We market analytical applications for the diagnosis a la carte of any genetic disease using the most advanced DNA sequencing technologies, also providing a genetic coun-

selling service. We provide molecular genetic testing services, among others, to hospitals, the pharmaceutical sector, the food sector and, in general, to all public and private research centers.

- **Services:** Clinical Services: Human Genetic Diagnostics Tests. Genetic Counseling. Rare Diseases. Molecular Genetic Analysis a la carte. Molecular Biology Services: DNA Sequencing. Genetic analysis on demand (Animals, plants, microorganisms). Massive sequencing of genomes. Transcriptomics. Metagenomics. Research Services: Development of R & D projects in the field of genomics.

- **Interest areas:** Our company is actively working with various companies and public and private research institutions for the development research projects in any scientific area where our expertise in Genomics, Genetics, Biochemistry and Molecular Biology can be helpful. The company has been a pioneer in DNA sequencing and in particular in the introduction of new massive sequencing technologies and in 2007 founded the company Lifesequencing SL who settled in Spain the first massive sequencing platform's most advanced in the market, the GS-FLX (454) Sequencer, with the aim of making available to the companies and the scientific community one of the most powerful tools that currently exist for better understanding of the genomes of living organisms from man to microorganisms.



## Sensia, S.L.

- **Contact:** Iban LARROULET, General Manager
- **Phone:** 34 918063089
- jsruiz@genetrix.es • <http://www.sensia.es>
- **Short description:** Sensia is the first Spanish Initiative to set up a leading company in the instrumentation

sector for life science research laboratories and for environment measurement. Sensia develops and commercialises portable, multibiosensor systems, based on technologies developed by the Biosensors Group of the National Microelectronics Centre, belonging to the Higher Council for Scientific Research.

- **Products:** SENSIA 2-SPR is an instrument based on Surface Plasmon Resonance (SPR) which enables comparative measurements to be made by incorporating channels. It also includes computer-controlled pumps and microfluid valves for sample injection. The Surface Plasmon resonance is a powerful technology for measuring biomolecular interactions, allowing real-time measurements without having to brand the analytes. The 2-SPR system has a large number of applications; in general all those studies based on biomolecular interactions: biochemical and chemical detection, discovery of medicines, diagnostics, proteomics, genomics, forensic medicine, food analysis, environmental monitoring, etc.

- **Interest areas:** The development of biosensors and their components. The development of new biosensor applications. Basic and clinical research. Diagnostic applications.



## Seprox Biotech

- **Contact:** Yago Romero. Commercial Director
- **Phone:** 34 914362036

- yromero@seprox.es • <http://www.seprox.es>

- **Short description:** SEPROX BIOTECH is a Spanish company created in December 2008. Between its main business areas is the production at industrial level of Hydroxytyrosol, Hydroxytyrosol Acetate and 2-3,4 Dihydroxyphenylacetic Acid.

SEPROX BIOTECH has developed its own production process using chemical synthesis and enzymatic biocatalysts. The great power of these compounds is its high antioxidant capacity together with its powerful free radical scavenging activity. Historically, these compounds were extracted from olive leaves, reaching lower purity levels than SEPROX BIOTECH products. They can be applied in cosmetics, nutrition, and pharmaceutical and food industries.

Its brand new production method gives SEPROX BIOTECH a competitive advantage over its competitors dedicated to extract polyphenolic compounds from natural sources, due to the quality levels (in terms of purity – over 99.7%– and deep control of impurities) that our products reach, and the reproducibility, which is extremely important when applied to nutrition, cosmetics or pharmaceuticals. SEPROX BIOTECH offers its products to interested companies, looking for long term and strategic relationships for the development of new products.



### Sigma Aldrich Química, S.A.

- **Contact:** Javier Márquez. General Manager
- **Phone:** 34 916619977 • [javier.marquez@sial.com](mailto:javier.marquez@sial.com) • <http://www.sigmaaldrich.com>

• **Short description:** Sigma-Aldrich is a leading Life Science and High Technology company. Our chemical and biochemical products and kits are used in scientific research and pharmaceutical development and our mission is to facilitate the science that makes the life better.

• **Products:** Our chemical and biochemical products and kits are used in scientific research, including genomic, functional genomics and proteomic research, animal models, biotechnology, pharmaceutical development and the diagnosis of diseases: Antibodies. shRNA & siRNA. Oligonucleotides. Media, reagents and sera for cell culture. Zinc Finger Nucleases for Gene Editing. Animal Models. Reagents for iPS cells, etc

• **Interest areas:** Sigma-Aldrich has developed an aggressive initiative for the evaluation of novel technologies that can enable the scientific community. This initiative provides Sigma-Aldrich with the opportunity to continue to offer new and novel technology-based products to researchers in academic, medical and industrial institutions, throughout the world. Technologies of Interest: Functional Genomics, RNAi, Gene Editing, Cell Biology, Live Cell Biosensors, Gene Expression, Proteomics, Stem Cells, Analytical and Material Science.



### Sistemas Genómicos, S.L.

- **Contact:** Lucía Pérez Navarro. Marketing department
- **Phone:** 34 902364669
- [lucia.perez@sistemasgenomicos.com](mailto:lucia.perez@sistemasgenomicos.com) • <http://www.sistemasgenomicos.com>

• **Short description:** Our main activity is research, development and commercialization of analytical applications based on genomics technology. We provided high added value services and products, as well as customized R&D projects addressed to Food analysis, Human Health, Biopharmaceutical and Genomic Research.

• **Products:** SG Food Analysis: GMO Analysis. Food Allergens Detection. Genetic Authentication in Food. Rapid Pathogen Detection. Genomic Identification and Typing. Water Analysis. Molecular Analysis Kits SG Human Health: Genetic Counseling. Genetic Diagnostics. Prenatal Genetic Diagnostics. Rare Diseases. Molecular Oncology. Genetics in Oncohematology. Preimplantation Genetic Diagnosis (PGD). Molecular Diagnosis Sets SG Research: DNA Sequencing. Ultrahigh throughput Sequencing Projects. Bioinformatics.

• **Interest areas:** Our company actively seeks the establishment of strategic alliances to promote R-D projects in Genomics. In 2008 the company has purchased the Ultrahigh Throughput Sequencing highest technology equipment available in the market: SOLID platform. And it allows us to collaborate and offering this new and exclusive technology to the whole scientific community.



### SOM Biotech SL

- **Contact:** Raúl Insa Boronat. CEO
- **Phone:** 34 934020150
- [insa@sombiotech.com](mailto:insa@sombiotech.com) • <http://www.sombiotech.com>

• **Short description:** Our objective is to discover, confirm, patent and develop or license the application of already known drugs in unknown indications (re-profiling). The aim of SOM is to perform at least 25 projects the first year, filing at least 6 patents and reaching licensing agreements.

• **Products:** The final product of SOM is a patent of use of a new indication for a known pharmaceutical drug and the know-how developed by the company for that achievement.

• **Interest areas:** The in-silico computerized platform can be dedicated to any therapeutic area. We plan strategic collaborations with in-vitro and in-vivo screening platforms and large pharmaceutical companies with commercial interest for further development of the reprofiled compounds.



### Stem Center, S.L.

- **Contact:** Yolanda Alemany
- [yalemany@stem-center.com](mailto:yalemany@stem-center.com) • <http://www.stem-center.com>
- **Phone:** 971 910074
- **Description:** Research and use of adipose derived stem cells in different clinical conditions.

• **Products and Services:** Extraction of adipose derived stem cells from lipoaspirates and autologous re-implantation into the patient for aesthetic or regenerative purposes.



### Suanfarma Biotech S.G.E.C.R. S.A.

- **Contact:** Gonzalo Marin. Managing Director
- **Phone:** 34 915671556

• gonzalomarin@suanfarma.com • <http://www.suanfarmabiotech.com>

• **Short description:** Suanfarma Biotech SGECE is a venture capital asset management company specialized in biotechnology authorized by the Spanish CNMV (equivalent to US SEC) in July 2007 and registered with number 66. Our mission is the management of biotechnology specialized funds and consultancy to biotechnology companies in several areas, such as business and commercial activities, industrial and R&D support, as well as regulatory guidance and financial advice. Suan Biotech I FCR authorized by CNMV in September 2007. The current portfolio of investments already managed by Suanfarma Biotech SGECE SA includes the companies: Vivia Biotech, 3P Biopharmaceuticals, Pevesa, Halotech, Salupharma, Biomedal, Clave Suan, Agrenvec & Noscira. Suan Biotech II FCR in process.

• **Interest areas:** SUANFARMA BIOTECH SGECE, S.A. evaluates investment opportunities with a strong and solid science, IP and growth potential. We look for projects and opportunities within universities, tech transfer units, R&D centers and within our national biotech and pharmaceutical market.



### Sylentis, S.A.U.

- **Contact:**
- **Phone:** 34 918047667 • [sylentis@sylentis.com](mailto:sylentis@sylentis.com) • <http://www.sylentis.com>
- **Short description:** Sylentis focuses on researching new therapeutic approaches based on

gene silencing. Sylentis is specialised in developing therapies via interference RNA, a powerful tool for rational drug design.

We are developing treatments for glaucoma and dry eye syndrome. Sylentis is also focusing on inflammatory bowel disease. Furthermore, Sylentis is focusing on post-traumatic neuron lesions and ischaemia, neurodegenerative diseases and dementia.

Sylentis has commenced a second Phase I/II clinical trial with SYL040012 for treating ocular hypertension.

• **Interest areas:** Because the release of RNAi in the body is an important part of these technologies, the company has a number of research projects under way regarding the controlled release of drugs, in cooperation with various public and private institutions.



### Synergia Bio

- **Contact:** Sergio Martín. Managing Director
- **Phone:** 34 965422028 • [smartin@synergiabio.com](mailto:smartin@synergiabio.com) • <http://www.synergiabio.com>
- **Short description:** Our goal is to participate in the renewable energies' value chain. Our experience in agronomy and molecular biology allow us to provide know-how to increase yields, reduce costs, processing and refining of biofuels or reduction in the emission of greenhouse gases.

We develop energy crops through the generation of new varieties or through specific enhancements designed to increase yield or improve transformation processes.

We perform new species adaptations and management of energy crops field trials.

We reduce carbon footprint by CO<sub>2</sub> fixation.

• **Interest areas:** Synergia Bio works in Bioenergy, using biotechnological tools in the renewable energies industry. We offer our expertise in energy crops for projects relating to biomass, biofuels, biodiesel, bioproducts or CO<sub>2</sub> Fixation. Our capabilities include molecular biology and genomics, along with agricultural development.

### Thrombotargets Europe, S.L.

- **Contact:** Ramón Béjar
- **Phone:** 34 936642040 • [bejar@thrombotargets.com](mailto:bejar@thrombotargets.com) • <http://www.thrombotargets.com>



THROMBOTARGETS EUROPE

• **Short description:** Thrombotargets Europe is a Biotech company focused on the development of new therapeutic treatments in the field of haemostasis. To achieve this goal Thrombotargets has developed proprietary High Throughput Screening Technologies that allow the Speedy-up of the Drug Discovery phase for the identification of innovative drugs that may improve the quality of life of the human being.

• **Products:** Drug Development: TT-173 (Topical Hemostat), and several programs focused on haemostasis and coagulation. Technological Platforms: BIOPLATFORMSCREEN (High Throughput Screening in haemostasis for the detection of anticoagulants, procoagulants, fibrinolytics, antifibrinolytics...)

• **Interest areas:** Collaborations in HTS projects; identification and development of new drugs in haemostasis; and diagnosis in haemostasis and cardiovascular. Alliances: with several public and private research centres and universities in Spain (CNB-CSIC, ICCS-CSIC, IQAC-CSIC, LIPPSO-UdG, CEREMET-UB, IUCT, CRC-CIM, Hosp. Vall Hebron...) and with international research centres (HEMOCENTRO Univ. Campinas...), and diverse companies for the screening and development of new drugs (SPECS, ASINEX, Instituto BIOMAR...).



## Valentia Biopharma

- **Contact:** José R. Tormo. R&D Head
- **Phone:** 34 96 354 38 42 • [jrtormo@valentiabiopharma.com](mailto:jrtormo@valentiabiopharma.com) • <http://www.valentiabiopharma.com>
- **Short description:** Biotechnology Company focused on the Development of New Drosophila models of Genetic Human Diseases, and Drug Discovery using Automated in vivo Screening Technologies in Drosophila

melanogaster models

- **Services:** Know-how and Biotechnology on the custom-made Design of Human diseases in Drosophila ;Drug Screenings on in vivo and in vitro Drosophila models; Bio-safety evaluation of chemicals for the European REACH regulation; Evaluation of Healthy Properties in nutritional produces.
- **Interest areas:** ValentiaBP is strongly interested in setting up collaborations with Bio-Pharma for the Development of Screening Platforms based on Drosophila possible models; Become and active participant of Networks Institutions interested on Rare Diseases (RD) Research and; Establish Collaborations towards offering a consolidated joint portfolio of analytical tests for the European REACH regulation.



## VidaCord, S.L.

- **Contact:** Angel G. Alvarez Ramos. Presidente y Fundador
- **Phone:** 34 918305785

- [agar@vidacord.es](mailto:agar@vidacord.es) • <http://www.vidacord.es>
- **Short description:** To process and criopreserve the cord blood that parents entrust VidaCord. To offer their children in the future the possibility to use these cells or their derivatives to treat certain diseases.
- **Services:** Obtaining, processing and criopreserving stem cells from blood cord
- **Interest areas:** Cell Therapy. Regenerative Medicine.



## Vircell, S.L.

- **Contact:** Almudena Rojas. Manager
- **Phone:** 34 958441264
- [arojas@vircell.com](mailto:arojas@vircell.com) • <http://www.vircell.com>

- **Short description:** To produce quality reagents and to develop innovating products that imply significant advances
- **Products:** Cell Culture: Cell lines, monoclonal antibodies, means of transporting virus. IFI: Immuno-fluorescence kits (single test and multitest). Brucellacapt: Diagnosis of Brucellosis. ELISA: Kits for the detection of specific antibodies. Controls of DNA/RNA: controls of PCR freeze-dried for an extensive range of infectious agents.



## Vita Aidelos

- **Contact:** Melania Rosique. Investigation Manager
- **Phone:** 34 944069689
- [info@vita-aidelos.com](mailto:info@vita-aidelos.com) • <http://www.vita-aidelos.com/>

• **Short description:** VITA AIDELOS was set up with the objective of creating a positive attitude towards Biotechnology while maintaining scientific rigour. We aim at bridging the gap between the scientific community and society. We collaborate with foundations, museums and scientific sites. We spread scientific advances made in the field of Biotechnology and help society understand science by encouraging critical analysis. VITA AIDELOS collaborates with the Genome Service: DNA Bank in the University of the Basque Country (UPV/EHU). Thanks to this combination of knowledge and technological experience we have already obtained three Spanish patents and three European ones. New educational material has also been developed: practice kits in Biotechnology to experiment in class or in scientific sites.

- **Products:** Patents, know-how Practice Kits in Biotechnology: Molecular Biology and Microbial Biotechnology Multimedia Products
- **Services:** Spreading and qualification in Biotechnology Practical consultancy Taking part in events and activities aimed at spreading Biosciences.
- **Interest areas:** Commercialization agreements. Taking part in R & D & I projects. Projects aimed at spreading science.



### Vivacell Biotechnology España, S.L.

- **Contact:** Dra. M.Luz Bellido Cabello de Alba. Research Director
- **Phone:** 34 957290666 / 637774192 • m.bellido@vivacellspain.com • <http://www.vivacellspain.com>
- **Short description:** VIVACELL BIOTECHNOLOGY ESPAÑA S.L. is a company focussed in Biomedicine and

Pharmaceutical Chemistry that investigates in new medical products derived from medicinal plants. The activities of the company are concentrated in the preclinical phase of drug discovery. We have developed our own platforms of primary screening for plant extracts.

• **Products:** Vivacell owns a large collection of plant-derived extracts biologically tested and a library of natural compounds. We have developed CDE-001, an standardised phytoextract with application in colon cancer and inflammatory bowel disease. In addition the company provides specialised in vitro and in vivo models for testing and developing pharmaceutical, nutraceutical and phytopharmaceutical compounds.



### Vivia Biotech, S.L.

- **Contact:** Andrés Ballesteros. Directot General
- **Phone:** 34 911293151 • admin@viviabiotech.com • <http://www.viviabiotech.com>
- **Short description:** Vivia Biotech pioneers the screening of thousands of drugs directly in patient's blood samples, an innovative Systems Biology research model, really translational, which has allowed

implementing for the first time in the world the Exvitech Tecnological Platform, property of Vivia Biotech.

"Smart" Reprofilng: by analyzing thousands of drugs on a patient's sample, we identify potentially effective drugs for a disease in the most direct way which, until now, was not possible.

The result of this process is to discover and bring to the market, for the benefit of the patient, new potential treatments against the disease based on new indications of already existing drugs comprising a faster and safer model to discover new treatments.

Personalized Medicine Test: or Hematological Cancers which can predict the best protocol treatments for each patient before its administration.

• **Interest areas:** Hematologic Cancer. Obesity. Autoimmune Diseases. Drug Screening.



### Vivotecnia Research, S.L.

- **Contact:** Antonio Vila Coro. Head of Business Development
- **Phone:** 34 917280715 • vilacoro@vivotecnia.com • <http://www.vivotecnia.com>

• **Short description:** Vivotecnia performs pre-clinical research on a contract basis. We offer reliable high quality investigation for the cosmetic, pharma and biotech industry.

• **Services:** We offer solutions to research and development projects. We can perform a wide range of efficacy and toxicity studies. We are certified to work under GLP standards and can work with rodents, non rodents and dogs as required by FDA, EMEA and the rest of agencies around the world.

• **Interest areas:** Activity, efficacy and toxicity studies in in vitro and in vivo models. Managing services for animal facilities and animal models. Animal facility services and rooms to rent.



### Zeltia

- **Contact:** Carmen Eibe. Projects Coordination Director
- **Phone:** 34 914444500 • ceibe@zeltia.com • <http://www.zeltia.com>
- **Short description:** Founded more than 70 years since its origin Zeltia group has been involved in the

biopharmaceutical and chemical. Investigated to improve the quality of life for patients, so each year we invest more resources in R + D + i in order to provide innovative treatments

In the biopharmaceutical sector differ several lines of research: Oncology, Central Nervous System, molecular diagnostics and genetic identification and RNAi (RNA interference)


In the field of consumer chemical there are several business lines: manufacture and sale of products for home care, manufacturing and sale of paints and protective coatings timber for professional and DIY.

• **Interest areas:** Zeltia since its beginnings has collaborated and continues collaborating actively with academics and public centers, with same and large businesses of the sector biopharmaceutical and of the chemical, so much national as international sector.

# A.1.

Who is who?  
Other Organizations Members

asebio





## BioBasque, la Bioregión Vasca

- **Contact:** Dr. María Aguirre. BioBasque Agency Manager
- **Phone:** 34 946555155
- <http://www.biobasque.org> • [biobasque@spri.es](mailto:biobasque@spri.es)

- **Short description:** To develop a new business sector related to life sciences, contributing to diversify the current industrial tissue and to maintain competitiveness in an international context.
- **Products:** BioBasque is represented by the BioBasque Agency, a one-stop location for biosciences in the Basque Country, and the instrument created to implement the strategy and to co-ordinate the relevant stakeholders.
- **Interest areas:** BioBasque is interested in establishing contacts with equivalent organisations, and other type of entities, that contribute to support the growth of the biocluster. It is equally interested in contacting companies wishing to establish operations in southern Europe.



## BIOIBAL (Cluster biotecnológico de las Islas Baleares)

- **Contact:** Pep Lluís Pons Hinojosa. General Manager
- **Phone:** 34 871230022
- [info@bioibal.org](mailto:info@bioibal.org) • <http://www.bioibal.org>

• **Short description:** BIOIBAL's mission is to promote biotech sector in Balearic Islands and help to create a suitable environment for adding value in Balearic research. Activity: Identify projects to increase biotech companies competitiveness and generation of public-private initiatives. Competences and fields intervention: Fostering relationships and synergies between all the stakeholders located in the area and encourage networking with other clusters and agencies. Internationalizations, promotion the participation of Balearic island companies in International fairs and congresses in the sector.

• **Services:** Research and Knowledge consulting for its members: Organize government subsidies, research grants and other sources of financing. Organize biotechnological events. Provide an employment and internship database to assist both employers and possible candidates. Offer consulting services on technical, legislative and market aspects. Promote internationalization and the establishment of alliances and R&D collaborations. Assistance on the creation of SMEs biotechnology companies. Represent the sector's interest in front of Governmental agencies. Facilitate the transfer and implementation of biotechnology into sectors where it is traditionally used as well as untraditional sectors.



## Bioregió de Catalunya (BIOCAT)

- **Contact:** Montse Daban. Communications and External Affairs, Director
- **Phone:** 34 933103330
- [mdaban@biocat.cat](mailto:mdaban@biocat.cat) • <http://www.biocat.cat>

• **Short description:** Biocat is the Catalonia biocluster organization with the aim to promote biotechnology and biomedicine in Catalonia. It is fostered by the Government of Catalonia and it is participated by companies and public

research institutions

• **Services:** Our main goals are: Facilitate networking among the different stakeholders. Foster biotechnology as a key economic driver for the country. Promote Catalonia biotechnology at the world stage. Inform and contribute to a better understanding and perception of biotechnology.



## BIOVAL

- **Contact:** María Eugenia Hernández de Pablo
- **Phone:** 34 902889990
- [info@bioval.org](mailto:info@bioval.org) • <http://www.bioval.org>

• **Short description:** BIOVAL was formed at the end of 2006 to increase the opportunities and further develop the biotechnology sector and become a means of growth, both socially and economically, for the Valencian Region.

BIOVAL is composed of more than 50 biotechnology companies located in the Valencian Region, as well as research and technology centers, universities, and hospitals whose R&D are oriented towards biotechnology.

• **Services:** Foster cooperation between biotechnology companies and organizations in order to better develop the Valencian region as a BioRegion.

Represent the sector's interest in front of Governmental agencies.

Manage a calendar of events for relevant courses.



## Centro Nacional de Investigaciones Oncológicas, CNIO

• **Contact:** José Ignacio Fernández Vera. Director of Support to the Investigation

• **Phone:** 34 912246900 • vera@cnio.es • <http://www.cnio.es>

• **Short description:** Basic and applied research under an integrated approach, fostering the interaction of basic research with of molecular diagnostics programmes and of the discovery of new drugs, all supported by a solid equipment and technical services infrastructure.

• **Services:** Undertaking research to enable the new, more efficient diagnosis and treatment methods to be obtained for oncological diseases. The transfer of scientific knowledge into clinical practice, so that scientific progress has an effect on our healthcare system as early as possible, and thus on patient welfare. The transfer of technology developed in the CNIO to innovating companies. To set up a new and more effective management system in the European scientific environment.



## Centro Tecnológico LEITAT

• **Contact:** Joan Parra. General Manager

• **Phone:** 34 937882300 • info@leitat.org • <http://www.leitat.org>

• **Short description:** LEITAT Technology Centre aims to collaborate with companies through research initiatives, developments and innovation pathways to add value to products, processes and tasks in different economic sectors, including the pharmaceutical, cosmetic, biomedical, cancer, biotechnology, nanotechnology and biomaterials and others.

In addition to the promotion of R+D+i, LEITAT's objectives are the technology transfer and scientific development under sustainability, responsibility, integrity and independence criteria.

• **Services:** Generation of monoclonal antibodies. Drug repositioning. In vitro and in vivo pharmacological characterization of therapeutical agents. Identification and validation of new biomarkers. Design and characterization of tools, instruments and devices for diagnosis, prognosis and monitoring. Characterization of antimicrobial properties, antifungal and anti dust mite. Determination of drug levels in biological fluids. Determination of the effectiveness of cosmetic active principles. Implementation of ADME studies and biocompatibility. Design and development of enzymatic and microbial bioprocesses. Industrial microbiology: screening and isolation of microbial strains of interest. Biofunctionality study with characterization of antimicrobial properties, anti-fungal, anti dust mite and prebiotic characteristics. Microencapsulation of different active ingredients with wide applications in many sectors. Determination of inorganic nanoparticles and their toxicity profile.



## CIBER BBN

• **Contact:** Begoña Pérez. General Manager

• **Phone:** 34 976512368 • bperez@ciber-bbn.es • <http://www.ciber-bbn.es>

• **Short description:** To improve the technological level of national industry in this field. To favour the

emergence of specialists with a high level of training in health technologies.

To increase the presence of Spain in decision-making forums and international research networks in this field

• **Products:** CIBER-BBN Research Infrastructure on Biomedicine: Production of Biomolecules Platform; Production of Biomaterials and Nanoparticles Platform; Tissues, Biomaterials and Surfaces Characterization Platform; Bioimaging Platform; High-performance computing Platform.

• **Interest areas:** BIOENGINEERING AND BIOMEDICAL IMAGING -Multimodal diagnosis -Intelligent devices BIOMATERIALS AND TISSUE ENGINEERING -Regenerative medicine (Scaffold-based Tissue Engineering; Cell therapy; Cell biophysics) -Endoprotheses and implants NANOMEDICINE -Molecular diagnosis and biosensors. -Therapeutic nanoconjugates and drug delivery systems.



## CIBERER

• **Contact:** Ingrid Mendes. Project Manager

• **Phone:** 34 963394789 • imendes@ciberer.es • <http://www.ciberer.es/>

• **Short description:** CIBERER's main objective is to become an international reference centre for re-

search on rare diseases, with emphasis on translational research. The scientific knowledge generated by the groups in CIBERER is intended to be applied in clinical practice in the patient's benefit.

• **Services:** The CIBERER main services are related to: Collaborative research projects on rare diseases Research platforms infrastructures Knowledge/Technology transfer

• **Interest areas:** Genetic and molecular diagnosis Development of advanced therapies. Gene therapy and cell therapy. Clinical trials and orphan drugs. Training Programmes Research collaborative projects.

## A.1. | Who is who? Other Organizations Members



GOBIERNO  
DE ESPAÑA

MINISTERIO  
DE CIENCIA  
E INNOVACIÓN



### Consejo Superior de Investigaciones Científicas, CSIC

• **Contact:** Prof. José M. Guisán Seijas. Director de la Oficina de Transferen-

cia de Tecnología.

• **Phone:** 34 915855301 • [ott@csic.es](mailto:ott@csic.es) • <http://www.csic.es>

• **Short description:** A public research body, under the auspices of the Spanish Ministry of Science and Technology, that provides research capacity and human resources and materials in the development of new scientific knowledge and the transformation of these into processes and products of social and economic interest.

• **Services:** To draw up and execute scientific and technological research projects. To draw up and execute collaboration contracts and agreements with companies and with other social agents. To contribute to the analysis and selection of future scientific and technological aims and to advise public administrations on research and technological innovation matters. To foster progress in basic and applied research. To collaborate with the Regional Governments in subscribed research activities. To collaborate with the universities in research and higher education activities. To develop training programmes for researchers and technicians working in the field of science and technology. To collaborate with the National R&D Plan in advisory and management tasks commissioned and with the Regional Governments who request this in the undertaking of their science policies.

• **Interest areas:** Projects in all the biotechnology and biomedicine areas and at the interface between biotechnology and organic chemistry, analytical chemistry, food technology, applied physics, etc. Collaboration with universities, technological centres, industries, etc. to enhance the flow that transforms basic science into social well-being.



### Fundación GAIKER

• **Contact:** Maitane Ipiñazar. Biotechnology Area Market Coordinator

• **Phone:** 34 946002323 • [mark@gaiker.es](mailto:mark@gaiker.es) • <http://www.gaiker.es>

• **Short description:** GAIKER is a Technology Centre whose objectives are to carry out research and supply reliable, innovative technological solutions which give value to the company, contributing to its technological development and its competitiveness through the generation, gathering, adaptation and transfer of innovative technolo-

gies in a sustainable manner. It also assumes the development of opportunities in emerging economic activities, all within a framework of collaboration with other agents.

• **Services:** Cell culture. Proteomics/ Genomics. Microbiology. Fluorescence Microscopy. Surface Plasmon Resonance (SPR). Applied Molecular Biology (PCR, RT-PCR, etc.) In order to carry out "In Vitro Toxicology" studies in pharmaceutical products, we have the Good Laboratory Practice Certificate (GLP). We are mainly focused on Health, Pharmaceutical, Food, Fine Chemistry and Agriculture, Industrial Chemistry and Services sectors

• **Interest areas:** Biodetection systems: BioRecognition molecules immobilization processes on surfaces. BioDetection systems development. Identification and development of target molecules. **Omnics:** Genomics, Proteomics. **In Vitro Test:** Efficacy evaluation. ADME. Toxicity of drugs and nanoparticles.



### Fundación Inbiomed

• **Contact:** Jose Manuel Franco. General Manager

• **Phone:** 34 943309074 • [jmfranco@inbiomed.org](mailto:jmfranco@inbiomed.org) • <http://www.inbiomed.org>

• **Description:** Development of new products and cell therapy medicinal products, focusing on the biology of adult stem cells and embryonic / reprogram (iPS) and its application in three fields, cancer, neurodegenerative diseases and cardiovascular diseases.

Provision of research services and / or consultancy on advanced cell therapies related to three therapeutic areas, cancer, neurodegenerative diseases and cardiovascular diseases.

Cell production in GMP conditions and related technical services.

Service of viral production, cell separation (sorter), cell reprogramming and animal models for preclinical testing.

Models in vitro reprogrammed cells (iPS) for drug testing.

• **Interest areas:** Partnerships with nanotechnology companies to develop specific biomaterials for future combination with cell therapy and / or paracrine factors of regeneration.

Partnerships with organizations or companies for the development of areas related to our research programs in the field of tissue engineering and personalized medicine.



## Fundación MEDINA (Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía)

- **Contact:** Olga Genilloud. Scientific Director
- **Phone:** 34 958993965 • [olga.genilloud@medinaandalucia.es](mailto:olga.genilloud@medinaandalucia.es) • <http://www.medinaandalucia.es>
- **Short description:** Fundación MEDINA is a non-profit public-private partnership between Merck Sharp and Dohme

de España S.A., the Junta de Andalucía and the University of Granada, to discover innovative compounds and therapies for unmet medical needs. Research activities at MEDINA are focused on: I. Discovery of new compounds and therapies that could be offered as new leads for development by industrial companies Offer of high throughput screening services for lead discovery on therapeutic targets developed by customers and compound profiling services for their drug candidates

• **Products:** New leads from microbial natural products collections in therapeutic areas identified as top priority by the national and regional Spanish Health Systems. Highly automated screening platform: evaluation of potential cardiovascular toxicities and adverse drug metabolism effects (ADME/TOX) of drug candidates in development. Ion channels assays (hERG, Cav1.2, Nav1.5) Drug metabolism assays (CYP inhibition and induction) Off-target interactions (neurotransmitter receptors, PPARs).

• **Interest areas:** Discovery of novel therapeutics from microbial natural products collections in: infectious diseases (including tuberculosis and parasitic diseases), oncology, immunoregulation and rare diseases. Study of potential cardiovascular and neuronal safety risks, and drug-drug interactions of new leads in early stages of the drug-discovery process.



## Fundación Parque Científico de Madrid (PCM)

- **Contact:** Antonio R. Díaz. General Manager
- **Phone:** 34 914972400 • [parque.cientifico@pcm.uam.es](mailto:parque.cientifico@pcm.uam.es) • <http://www.fpcm.es>

• **Services:** Business Development: Support for entrepreneurs, Business Creation, Business Incubator, Bioincubator, Access to financing, scientific and university environment. -Scientific Services: Genomics, Proteomics, Micro-analysis of materials, Bio-IT, Biotransfo

• **Interest areas:** The creation of companies with a technological base. Science services to biotech companies. Large scientific facilities Technical assistance for the creation and management of science and technology parks.



Fundación Aula Dei  
PARQUE CIENTÍFICO TECNOLÓGICO  
AGROALIMENTARIO

## Fundación Parque Científico Tecnológico Agroalimentario Aula Dei (Fundación PCTAD)

- **Contact:** Susana Martínez Hernández. Fundación Aula Dei Director
- **Phone:** 34 976716976 • [smartinez@aragon.es](mailto:smartinez@aragon.es) • <http://www.pctad.com>

• **Short description:** To connect de research centres and the companies. To support and encourage the companies within the agricultural and environmental sector to look for scientific and technological solutions. To transfer the results of the research centres linked to the Park to the production fabric. To spread the researcher's work to enhance its visibility. To arrange and promote the existing technology offer. To detect and give solution to the new technologies needs To encourage the creation and consolidation of innovative companies within the sector.

• **Products:** Management of R + D + i contracts between companies and research centres. Advice regarding R & D projects. Business incubator. Innovation and Creation of new technology based firms Programme. Spin off Programme. Cooperation networks for knowledge and technology transference. Transferring and putting the technology on the market. Regional, National and International Financing of R + D + i projects. Training: specialised postgraduate and advanced courses for professionals.

• **Interest areas:** Animal Health and Production. Environmental Technology. Forest Resources. Freshwater Resources and irrigation technology. Agricultural Economy. Vegetal health and Nutrition. Food quality and security technology Biotechnology. Genetic Improvement. Agrifood production and container. Bio-mass. Wine technology.



## Fundación Parque Tecnológico de Ciencias de la Salud de Granada (PTS)

- **Contact:** Jesús Quero Molina. Manager
- **Phone:** 34 958535050 • [jquero@ptsgranada.com](mailto:jquero@ptsgranada.com) • <http://www.ptsgranada.com>
- **Short description:** The promotion of interdisciplinary research in biomedicine at an international level. The protection and transfer of knowledge. "The consolidation of health sciences business framework based on technology and aimed at clinical practice. "Being a centre of excellence for healthcare.
- **Services:** RESEARCH SERVICES - Library - Cell Culture - DNA Sequencing - Genomics and Proteomics - Oligo-

nucleotide Synthesis SERVICES OF TECHNOLOGICAL INNOVATION -Funding of the I+D+i -Transfer of Technology -Industrial Property -Technological Alertness -Strategic R&D Management MANAGERIAL SERVICES -Services of EIBTs's creation -Services of incubation -Services of managerial development GENERAL SERVICES.

• **Interest areas:** Biotechnology and Human Health.



## Genoma España

- **Contact:** Belén Gilarranz. Communication Officer
- **Phone:** 34 914491250

- [belen.gilarranz@gen-es.org](mailto:belen.gilarranz@gen-es.org) • <http://www.gen-es.org>
- **Short description:** Promote the creation of value from knowledge in strategic areas of the National R&D&I Plan, especially in biotechnology, through technology transfer and training with the goal of improving the health and quality of life of citizens and the competitiveness of businesses, while establishing the framework for public-private partnerships.
- **Services:** Our main goals are: Promote the active support and coordination of research carried out in Spain. Make better use of research resources and results by promoting technology transfer and supporting the creation of technology-based companies. Undertake tasks of technology watch, prospective and strategic analysis. Help in the internationalization and in the promotion of the Spanish biotechnology sector. Bring biotechnology closer to society.



Industria, Innovación  
y Empleo

## Gobierno de La Rioja. Dirección General para la Innovación

- **Contact:** Javier Ureña Larragán. Director-General for Innovation

- **Phone:** 34 941291684 • [dg.innovacion@larioja.org](mailto:dg.innovacion@larioja.org) • <http://www.larioja.org>
- **Short description:** R+D and Innovation Policies Design Communication of the relevance of the R+D and Innovation issues Regional coordination of those activities Push up of the technology transfer Facilitate the growing up of new innovative companies Enlarge the research activity in La Rioja Be in the European R+D and Innovation Network Focus the local companies to the new technologies to improve their competitiveness
- **Services:** New Third R+D and Innovation Regional Plan 2.008-2.011 New Regional Law for R+D and Innovation Technology Surveillance and Prospective Support our companies to participate in R+D and Innovation projects Develop activities to transfer the biotechnological solutions to traditional companies Helping companies to reach funds for biotechnological projects Coordination of the Technologies Centres in La Rioja Communicate to a public of all ages the relevance of the biotechnology.



## Institut de Recerca Biomèdica de Lleida (IRBLleida)

- **Contact:** Elias Daura Oller. Managing Director
- **Phone:** 34 973702223
- [edaura@irbllleida.cat](mailto:edaura@irbllleida.cat) • <http://www.irbllleida.cat>

- **Short description:** IRBLleida aims to promote, develop, transfer, manage and disseminate biomedical research and research training in the field of life sciences and health.
- **Services:** Research and development collaborative. Clinical Trials.
- **Interest areas:** Biotechnology and Human Health. Food and Nutrition. Collaborative research projects. Clinical Trials.



## Instituto Andaluz de Biotecnología (IAB)

- **Contact:** Fernando Pliego Alfaro. Director
- **Phone:** 34 952134183 • [iab-secretaria@uma.es](mailto:iab-secretaria@uma.es) • <http://www.iab.cica.es>
- **Short description:** The IAB is a body of the Department of Innovation Science and Enterprise,

having among his objectives to promote and to dynamize Biotechnology in Andalusia from fields of Investigation, Technology Transfer and Enterprises. The IAB coordinates and promotes collaboration of all implicated agents in the biotechnological sector, optimizing available resources.

- **Products:** Scientific production-Technique of the IAB The IAB, currently has assigned 60 Andalusian Research Groups, belonging to all Andalusian Universities, as well as to the Andalusian Institute of Agricultural Investigation and Ecological Production (IFAPA) and to CSIC, agglutinating the greater effort in scientific knowledge in the area of Biotechnology in Andalusia.
- **Services:** Participating in the elaboration of Action Plans in Biotechnology. Elaborating reports on status of the Biotechnological Sector. Promoting and dynamizing the biotechnological transfer. Serving back-up and supporting research groups. Elaboration and diffusion of technical specialties of research groups and patent technical specifications. Helping in the search and member selection for business opportunities. Spreading and promoting the Biotechnological Sector in Andalusia: Conferences, Courses, Events, etc.



### Instituto de Salud Carlos III

- **Contact:** Julia Medrano Chivite. Area Chief
- **Phone:** 34 918222125 • [otri@isciii.es](mailto:otri@isciii.es) • <http://www.isciii.es>

• **Short description:** A public research body, whose mission is to foster, develop and render technical scientific services in the field of human health care.

• **Services:** Research into the different aspects relating to the application of genetic knowledge in diagnosis, therapy, the development of new drugs and epidemiology.

The development of innovation in telematics, bio-IT, genomics and proteomics and other new technologies applied to health care.

The conservation of international standards and the preparation and conservation of national standards.

Awarding aid and subsidies for biomedical research.

Drawing up reports about healthcare technologies and services aimed at consolidating decision-making at the different levels of the National Healthcare System.

• **Interest areas:** Molecular Diagnosis. Telematics and Bio-IT. Proteomics and genomics. Healthcare technologies.



### NEIKER - Instituto Vasco de Investigación y Desarrollo Agrario

- **Contact:** Dra. Sonia Castañón de la Torre. Biotechnology Department Head

- **Phone:** 34 945121313 • [scdelatorre@neiker.net](mailto:scdelatorre@neiker.net) • <http://www.neiker.net>

- **Short description:** NEIKER is a Public Institute of Research and Technological Development that seeks

generating knowledge and offering services that contribute to the improvement of Agriculture, Food and Environmental sectors. Biosciences and biotechnology are the instruments with which to contribute actively to the economic and social development, improving competitiveness and sustainability.

• **Services:** Activity is focused on R&D, laboratory analysis, technical advice for the Agricultural, Food and Environmental sectors, technical support under emergency alerts, new technology transfer to emerging companies and development of new technology-based companies. Main working fields: genomics, in-vitro cultures, identification and production of biomolecules, food biosecurity, application of biotechnology to animal health and environment.

• **Interest areas:** Industrial applications for new biomolecules. New applications of genomics and in-vitro cultures. New drug development for the Animal Health sector. Diagnosis in Food biosecurity. Systems of environmental evaluation.



### Parc Científic de Barcelona (PCB)

- **Contact:** Fernando Albericio

- **Phone:** 34 934034475 • [administracio@pcb.ub.es](mailto:administracio@pcb.ub.es) • <http://www.pcb.ub.es>

- **Short description:** To potentiate quality research with the support of a wide range of technologies

To revitalize the relation between university and business

To promote the creation of new companies and institutions

To further the science-society dialogue and encourage careers in science

• **Services:** Technological facilities by Technology Platforms and Scientific Services of the PCB and UB

• **Interest areas:** Medicinal chemistry, nanotechnology, structure-based drug discovery, ecotoxicology, proteomics, transcriptomics, animal models of disease.



### Sociedad Española De Bioquímica y Biología Molecular (SEBBM)

- **Contact:** Isabel Perdigüero. Technical Secretariat

- **Phone:** 34 915613381 • [sebbm@sebbm.es](mailto:sebbm@sebbm.es) • <http://www.sebbm.es>

- **Short description:** Created in 1963 and with more than 3500 members, has the following objectives: i) promoting research; ii) boosting transfer of knowledge to the industry; iii) improving teaching; iv) facilitating contacts

with interested stakeholders; v) fostering the internationalization of Spanish science; vi) informing the Spanish society about scientific progress; and, vii) contributing to strengthen the social and economical influence of Science.

• **Services:** Technology development and transfer in biochemistry and molecular biology and biotechnology. R&D Research in Biochemistry and molecular biology and biotechnology R&D training in Biochemistry and molecular biology and biotechnology R&D services in Biochemistry and molecular biology and biotechnology

• **Interest areas:** To promote transfer of results and technology between members of the Society and partners of ASEBIO To co-organize courses, workshops of interest in Biotechnology To participate in Congresses and Meetings in Biotechnology.



## Universidad de Navarra

### Universidad de Navarra

- **Contact:** José Manuel Zumaquero/ María Font. Legal Representative/ Person for Scientific
- **Phone:** 34 948425600
- [jmzumaquero@unav.es](mailto:jmzumaquero@unav.es) • <http://www.unav.es>

• **Short description:** Higher education, basic and applied research and specialised medical attention.



### Universidad Europea de Madrid

- **Contact:** Maria Junco. Area Manager Pharmacy and Biotechnology
- **Phone:** 34 912115277
- [maria.junco@uem.es](mailto:maria.junco@uem.es) • <http://www.uem.es>

Laureate International Universities

• **Short description:** Providing students with an excellent university education in order to acquire both academic knowledge and practical skills which will allow them a rapid incorporation into the professional world. Promoting an international perspective by encouraging students to study at Universities abroad and facilitating internships in foreign companies

• **Services:** A university education that includes Bachelor s and Graduate Degrees in a broad range of programs. Bachelor s Degrees and Double Degrees are offered in Pharmacy and Biotechnology, in Health and Biomedical sciences area. Their cutting-edge practical approach prepares students to work both in research and management of biotechnology companies.

• **Interest areas:** Internships required for students in their final year of studies in Biotechnology companies. Undergraduate and Graduate training in Biotechnology: courses, seminars, etc Collaboration agreements with private companies to develop research projects at UEM Laboratories.



### Universidad Pablo de Olavide

- **Contact:** Cristina Moreno. Technician of the Strategic Planning Office
- **Phone:** 34 954977814
- [planestrategico@upo.es](mailto:planestrategico@upo.es) • <http://www.upo.es>

• **Short description:** To achieve such a research dimension that constitutes an outstanding reference

at the international level To promote both technology transfer and wealth development To support innovation To promote social development

• **Services:** Education and Training Research Advice on business administration and management

• **Interest areas:** Collaboration with university research teams. Collaboration agreement for professional training of students and graduates of the university. Location of entrepreneurial firms in the UPO campus.



### Veterindustria

- **Contact:** Santiago de Andrés. Director General
- **Phone:** 34 913692134
- [veterindustria@veterindustria.com](mailto:veterindustria@veterindustria.com) • <http://www.veterindustria.com>
- **Short description:**

To defend the collective interests of the associated companies that manufacture and/ or commercialise the following products and services in Spain: Veterinary medicines, animal healthcare and nutritional products and additives for animal nutrition, through its different co-ordination, advisory and communication services, to thus promote all the aspects of the Animal Healthcare and Nutrition Industry, benefiting both the sector and society in general. To promote research, technology development and innovation in the field of animal health through the creation of the Spanish Technology Platform for Animal Health, Vet+i.

asebio



GOBIERNO  
DE ESPAÑA

MINISTERIO  
DE INDUSTRIA, TURISMO  
Y COMERCIO

ICEX

INSTITUTO  
ESPAÑOL  
DE COMERCIO  
EXTERIOR



EUROPEAN UNION  
EUROPEAN REGIONAL  
DEVELOPMENT FUND  
A WAY TO MAKE EUROPE